Category: For physicians

  • A bedside electrocardiogram monitor displaying heart rate and rhythm readings

    Neuropathy and Chronic Pain as Cardiovascular Risk Markers: The Screening Signal in Plain Sight

    Neuropathy and Chronic Pain as Cardiovascular Risk Markers: The Screening Signal in Plain Sight

    Peripheral neuropathy and chronic pain are cardiovascular risk markers. In NHANES, neuropathy found on monofilament testing was tied to higher cardiovascular mortality in adults with diabetes (HR 1.66), and in the UK Biobank chronic widespread pain carried a 48% higher adjusted risk of cardiovascular disease. A patient who presents with burning feet or daily pain warrants a cardiometabolic and autonomic workup.

    The patient with burning feet gets a gabapentinoid. The patient with diffuse pain gets a referral to rheumatology. Neither usually gets a cardiovascular risk assessment beyond the lipid panel already on file. The cohort data say both should.

    How strongly does peripheral neuropathy predict death?

    Hicks and colleagues followed 7,116 NHANES participants aged 40 and older who had standardized monofilament testing between 1999 and 2004. Neuropathy prevalence was 13.5% overall: 27.0% with diabetes and 11.6% without. Over a median 13 years, 2,128 died, 488 from cardiovascular causes.

    All-cause mortality per 1,000 person-years ran 13.0 with neither diabetes nor neuropathy, 27.1 with diabetes alone, 34.3 with neuropathy alone and 57.6 with both. After adjustment, neuropathy was associated with all-cause mortality (HR 1.49) and cardiovascular mortality (HR 1.66) in participants with diabetes. Without diabetes, the all-cause association held (HR 1.31); the cardiovascular association (HR 1.27, 95% CI 0.98 to 1.66) did not reach significance.

    Two things follow. Neuropathy without diabetes carried a higher crude death rate than diabetes without neuropathy. And the case definition was a monofilament, which detects large-fiber loss; small-fiber disease, which the monofilament misses, was not counted. The true burden is likely underestimated.

    What does cardiovascular autonomic neuropathy add?

    Autonomic involvement is the part of neuropathy that reaches the heart directly. Maser’s meta-analysis of 15 studies in diabetes found a pooled relative risk of mortality of 3.45 (95% CI 2.66 to 4.47) when cardiovascular autonomic neuropathy was defined by two or more abnormal tests, against 1.20 when a single measure was used. In ACCORD, among 8,135 participants with type 2 diabetes at high cardiovascular risk, baseline autonomic dysfunction defined by heart rate variability and QT index carried 1.55 to 2.14 times the mortality risk, depending on the definition, over a mean 3.5 years.

    The practical lesson is in Maser’s split. A single abnormal heart rate variability value is a weak signal; a battery that confirms dysfunction on two or more tests is a strong one. That argues for cardiac autonomic reflex tests alongside heart rate variability, not either alone.

    Is chronic pain itself a cardiovascular risk factor?

    In the UK Biobank, Rönnegård and colleagues classified 475,171 participants by pain duration and distribution and followed them for a median of seven years. After adjusting for age, sex, established cardiovascular risk factors, physical activity, anxiety, depression, cancer, chronic inflammatory disease, pain and anti-inflammatory medication and socioeconomic status, chronic localized pain carried an HR of 1.14 and chronic widespread pain an HR of 1.48 for composite cardiovascular disease. The population attributable risk for chronic pain was 8.6%, against 7.3% for diabetes.

    A 2026 meta-analysis of 18 studies on chronic widespread pain narrows the claim honestly. The risk of atherosclerotic disease was elevated in minimally adjusted models (RR 1.94) and remained elevated in maximally adjusted models (RR 1.53, 95% CI 1.27 to 1.86). For cardiovascular mortality the minimally adjusted RR was 1.61 but fell to 1.12 (95% CI 0.93 to 1.34) with full adjustment, heterogeneity was high, and publication bias was suspected in the mortality analysis. The atherosclerosis signal is consistent; the mortality signal is not settled. The authors’ conclusion is the screening argument: people with widespread pain may be an under-recognized high-risk group that would benefit from proactive cardiovascular assessment.

    What biology links nerves, pain and arteries?

    Shared terrain rather than a single pathway. Adiposity predicts neuropathy independent of glycemia. In KORA F4/FF4, 513 adults aged 62 to 81 followed for 6.5 years, obesity carried an OR of 3.47 for incident distal sensorimotor polyneuropathy and each 5 cm of waist an OR of 1.22, with no difference by diabetes status. The chemokines CCL7 and CXCL10 each mediated up to 11% of the effect. Callaghan found polyneuropathy in 3.8% of lean controls and 11.1% of normoglycemic participants with obesity, rising to 29% with prediabetes and 34.6% with diabetes; waist circumference was independently associated.

    At the nerve, cytokines, chemokines and lipid mediators from inflamed tissue sensitize nociceptors and promote the maladaptive plasticity that sustains neuropathic pain. The same metabolic inflammation drives insulin resistance and atherosclerosis. Then behavior closes the loop: pain reduces activity, fragments sleep and isolates people, and each of those worsens insulin resistance. NSAID exposure adds its own cardiovascular load; see NSAID cardiovascular risk in chronic pain.

    What does the workup look like?

    • Small fibers: sudomotor testing, read against the device’s reference bands. Burning feet with a normal monofilament exam often point here; see fibromyalgia and small fiber neuropathy.
    • Autonomic: heart rate variability plus cardiac autonomic reflex tests, defining dysfunction on two or more abnormalities.
    • Vascular: ankle-brachial index and arterial stiffness, because neuropathic feet mask claudication.
    • Adiposity: waist and body composition.
    • Laboratory: LP-IR, fasting insulin and HOMA-IR (fasting insulin above 10 µIU/mL is treated as high risk at the Padda Institute), GGT (cutoff above 20 U/L), oxidized LDL with the omega-3 index and omega-6 to omega-3 ratio, hs-CRP, 25-OH vitamin D, homocysteine, and B12 with MMA or holotranscobalamin. The last three matter twice in this population because they are also neuropathy causes. See hyperinsulinemia screening in neuropathic pain.

    Build it into intake for pain and neuropathy referrals through standing orders, and use specialty applications for the pain-practice version of the workflow.

    Dr. Padda has worn an EKG through his own heat-exposure experiments and watched his rhythm change in real time. The autonomic nervous system is not an abstraction on a report; it is the wiring between how a person lives and how their heart behaves, and in a pain patient it is usually already frayed.

    Frequently asked questions

    Does treating neuropathy or pain lower cardiovascular risk?

    That has not been shown in a trial. Maser’s meta-analysis closed by calling for studies of whether early identification of autonomic neuropathy reduces mortality. The value of screening now is finding the shared drivers, adiposity, insulin resistance and inflammation, that are treatable and that the pain presentation would otherwise hide.

    Is a normal monofilament exam enough to rule out neuropathy-related risk?

    No. The monofilament detects large-fiber loss. Small-fiber and autonomic involvement can be present with a normal monofilament, which is why sudomotor and autonomic testing belong in the screen.

    Add the cardiovascular screen to your nerve and pain patients

    Sudomotor, autonomic, vascular and body composition testing in one visit, with a report written for the referring physician.

    4477 Woodson Rd, Suite 201, St. Louis, MO 63134. Monday to Friday, 9:00 a.m. to 5:00 p.m. Please do not send symptoms, diagnoses or images through a web form — a website form is not a secure medical channel. Send your name and number and we will call you back.

    References

    • Hicks, C. W., Wang, D., Matsushita, K., Windham, B. G., & Selvin, E. (2021). Peripheral Neuropathy and All-Cause and Cardiovascular Mortality in U.S. Adults : A Prospective Cohort Study. Annals of Internal Medicine, 174(2), 167-174. https://doi.org/10.7326/M20-1340 (PMID 33284680)
    • Maser, R. E., Mitchell, B. D., Vinik, A. I., & Freeman, R. (2003). The association between cardiovascular autonomic neuropathy and mortality in individuals with diabetes: a meta-analysis. Diabetes Care, 26(6), 1895-1901. https://doi.org/10.2337/diacare.26.6.1895 (PMID 12766130)
    • Pop-Busui, R., Evans, G. W., Gerstein, H. C., Fonseca, V., Fleg, J. L., Hoogwerf, B. J., et al. (2010). Effects of cardiac autonomic dysfunction on mortality risk in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Diabetes Care, 33(7), 1578-1584. https://doi.org/10.2337/dc10-0125 (PMID 20215456)
    • Rönnegård, A.-S., Nowak, C., Äng, B., & Ärnlöv, J. (2022). The association between short-term, chronic localized and chronic widespread pain and risk for cardiovascular disease in the UK Biobank. European Journal of Preventive Cardiology, 29(15), 1994-2002. https://doi.org/10.1093/eurjpc/zwac127 (PMID 35727954)
    • Rönnegård, A.-S., Schillemans, T., Äng, B., Boersma, K., Ärnlöv, J., & Tseli, E. (2026). Chronic widespread pain and the risk of cardiovascular disease-a systematic review and meta-analysis. Pain, 167(6), 1295-1307. https://doi.org/10.1097/j.pain.0000000000003965 (PMID 41972388)
    • Schlesinger, S., Herder, C., Kannenberg, J. M., Huth, C., Carstensen-Kirberg, M., Rathmann, W., et al. (2019). General and Abdominal Obesity and Incident Distal Sensorimotor Polyneuropathy: Insights Into Inflammatory Biomarkers as Potential Mediators in the KORA F4/FF4 Cohort. Diabetes Care, 42(2), 240-247. https://doi.org/10.2337/dc18-1842 (PMID 30523031)
    • Callaghan, B. C., Xia, R., Reynolds, E., Banerjee, M., Rothberg, A. E., Burant, C. F., et al. (2016). Association Between Metabolic Syndrome Components and Polyneuropathy in an Obese Population. JAMA Neurology, 73(12), 1468-1476. https://doi.org/10.1001/jamaneurol.2016.3745 (PMID 27802497)
    • Ellis, A., & Bennett, D. L. H. (2013). Neuroinflammation and the generation of neuropathic pain. British Journal of Anaesthesia, 111(1), 26-37. https://doi.org/10.1093/bja/aet128 (PMID 23794642)
    • Hotamisligil, G. S. (2017). Inflammation, metaflammation and immunometabolic disorders. Nature, 542(7640), 177-185. https://doi.org/10.1038/nature21363 (PMID 28179656)

    Related reading

  • A physician in a white coat reviews a patient's screening results on a clipboard

    Adiposopathy and ASCVD: A Treat-Obesity-First Screening Protocol for Primary Care

    Adiposopathy and ASCVD: A Treat-Obesity-First Screening Protocol for Primary Care

    Screen adiposopathy the way you screen any cardiovascular risk factor: by measurement, not by BMI. A treat-obesity-first protocol pairs waist and body composition with vascular (ankle-brachial index, arterial stiffness), autonomic (heart rate variability, cardiac autonomic reflex tests) and laboratory markers of sick fat, then treats the adipose tissue itself instead of chasing each downstream number.

    Most primary care visits treat obesity as a background condition and its consequences as the work: titrate the antihypertensive, add the second diabetes drug, recheck the lipids. The 2026 Obesity Medicine Association statement asks for the order to be reversed. This is a practical version of what that looks like on a Tuesday afternoon.

    What does the 2026 OMA statement change?

    The statement frames obesity as a chronic disease that causes cardiovascular disease directly, through biomechanical “fat mass disease” and dysfunction of epicardial adipose tissue, and indirectly, through adiposopathic immune and endocrine abnormalities that drive type 2 diabetes, hypertension, dyslipidemia and thrombosis. Its management conclusion is a shift “from treating downstream risk factors to addressing excessive adipose tissue itself,” which it calls treat obesity first, and it recommends precision diagnostics as part of that approach.

    The underlying concept, adiposopathy, also explains why risk does not track fat mass neatly. Judging adipose tissue by function rather than quantity resolves most of the obesity paradoxes. For screening, that means the question is not “how heavy” but “how sick,” and BMI cannot answer it.

    What do SELECT, STEP-HFpEF and SUMMIT add to the case?

    Three randomized trials now connect treating adipose tissue to hard or patient-centered cardiovascular outcomes.

    • SELECT enrolled 17,604 adults aged 45 and older with established cardiovascular disease, BMI 27 or higher and no diabetes. Over a mean follow-up of 39.8 months, the primary outcome of cardiovascular death, nonfatal myocardial infarction or nonfatal stroke occurred in 6.5% on semaglutide 2.4 mg weekly versus 8.0% on placebo (HR 0.80, 95% CI 0.72 to 0.90). Adverse events leading to discontinuation were 16.6% versus 8.2%.
    • STEP-HFpEF randomized 529 patients with HFpEF and BMI 30 or higher. At 52 weeks, KCCQ clinical summary score improved 16.6 versus 8.7 points, body weight changed by -13.3% versus -2.6%, 6-minute walk distance by 21.5 m versus 1.2 m, and CRP by -43.5% versus -7.3%. Serious adverse events were 13.3% versus 26.7%.
    • SUMMIT randomized 731 patients with HFpEF and BMI 30 or higher to tirzepatide or placebo over a median 104 weeks. Cardiovascular death or worsening heart failure occurred in 9.9% versus 15.3% (HR 0.62, 95% CI 0.41 to 0.95), driven by worsening heart-failure events (8.0% versus 14.2%). Cardiovascular death alone was 2.2% versus 1.4%, with a wide interval that does not support a conclusion either way.

    Read the populations before applying the results. SELECT excluded diabetes and required established disease; both HFpEF trials required BMI 30 or more. None enrolled the multimorbid chronic-pain patient on several sedating medications who fills many primary care panels. The signal is consistent: reduce the adipose tissue and its inflammatory output and cardiovascular outcomes move. The plan for each patient is still built from that patient’s measurements.

    Who should be screened?

    Start from the criteria in who to test: adults over 50 with any cardiovascular risk factor, everyone over 70, and anyone with hypertension, overweight, diabetes or a smoking history. Add three groups the usual criteria miss:

    • Normal BMI with central adiposity. Waist adds risk information at every BMI level, and a consensus group has asked that it be recorded as a vital sign.
    • Chronic pain. In the UK Biobank, chronic widespread pain carried an adjusted HR of 1.48 for composite cardiovascular disease.
    • Peripheral neuropathy, which shares the inflammatory terrain and predicts mortality. The evidence is in neuropathy and chronic pain as cardiovascular risk markers.

    Expect a high yield. On NHANES 2009–2016 criteria, under 12.2% of US adults were metabolically healthy, and among adults with obesity the figure was 0.5%. On tighter cardiometabolic criteria, NHANES 2017–2018 put it under 7%. That is the general population, not a referral clinic’s.

    Which measurement maps to which pathway?

    Fat mass disease

    Bioimpedance body composition separates fat mass, lean mass and trunk fat, and flags the sarcopenic patient whose BMI understates risk. Indirect calorimetry gives a measured resting energy expenditure and respiratory quotient to build nutrition therapy from. Screen symptomatically for sleep apnea in parallel; the OMA statement treats it as a cardiovascular comorbidity of obesity.

    Sick fat disease

    Ankle-brachial index: in the ABI Collaboration’s 16 cohorts, an ABI of 0.90 or below roughly doubled 10-year total and cardiovascular mortality within every Framingham category and reclassified about 19% of men and 36% of women. Arterial stiffness and endothelial function: in the aortic PWV literature, each 1 m/s increment carried a 14% higher adjusted risk of cardiovascular events. The Measura index is oscillometric with PPG contour analysis, not carotid-femoral PWV; treat it as related evidence and trend it within the patient.

    Laboratory, in the order the derangement usually appears: LP-IR (rises before HbA1c), fasting insulin reported on its own and as HOMA-IR (the Padda Institute treats fasting insulin above 10 µIU/mL as high risk), GGT (risk cutoff above 20 U/L in the same clinic), oxidized LDL with the omega-3 index and omega-6 to omega-3 ratio, hs-CRP against the 1 and 3 mg/L bands, 25-OH vitamin D, homocysteine, and B12 with MMA or holotranscobalamin. See laboratory panels.

    The autonomic layer

    Heart rate variability and cardiac autonomic reflex tests detect cardiovascular autonomic dysfunction, which carries its own mortality signal, and sudomotor testing screens small-fiber involvement. Use a battery rather than a single index; the mortality association is far stronger when two or more abnormalities define the diagnosis.

    How does this fit into standing orders and documentation?

    Write the screen as a standing order triggered by the criteria above, run by trained technicians, with results returned to the ordering physician for interpretation. The templates are in standing orders, and reading the combined report is covered in interpreting the report. Re-measure after a meaningful change in weight or therapy so the patient sees the terrain respond, not just the scale. Body composition, BMI follow-up plans and cardiovascular risk assessment also support documentation for the annual wellness visit and quality reporting; see MIPS and quality reporting.

    Where does pharmacotherapy fit?

    GLP-1 receptor agonists and dual agonists have the outcome data above and may be part of the solution for specific patients, selected after the evaluation and monitored with the same measurements. They do not replace the behavioral work, which at the Padda Institute is 40 to 50% of the treatment protocol: lower acellular carbohydrate intake, removing industrial seed oils, protein and resistance training to prevent sarcopenic wasting during weight loss, sleep, and the social isolation that drives eating. On lipid therapy, interpret statin trials in the populations they enrolled and individualize in multimorbid patients rather than defaulting to dose escalation.

    Dr. Padda spent years telling patients with prediabetes that their A1c was fine. It was, by the cutoff. Their insulin, their liver and their nerves were not. That is the failure this protocol is built to prevent: a reassuring threshold standing in for a measurement nobody took.

    Frequently asked questions

    Should screening wait until BMI reaches 30?

    No. Waist circumference adds risk information at every BMI level, and central adiposity with insulin resistance is common at a normal BMI. That is why the screening trigger should be a measurement, not a BMI cutoff.

    Does an abnormal ABI or stiffness index change management if lipids are controlled?

    It changes the risk estimate. A low ABI reclassified roughly a fifth of men and a third of women in pooled cohorts. It strengthens the case for treating adiposity and insulin resistance aggressively and for re-measuring to confirm the vascular findings move.

    Build the protocol into your clinic

    We help practices set up standing orders, technician workflow and report interpretation for cardiometabolic and autonomic testing.

    4477 Woodson Rd, Suite 201, St. Louis, MO 63134. Monday to Friday, 9:00 a.m. to 5:00 p.m. Please do not send symptoms, diagnoses or images through a web form — a website form is not a secure medical channel. Send your name and number and we will call you back.

    References

    • Bays, H. E., Varney, C., Alexander, L., Ng, J., Tondt, J., Weber, C., et al. (2026). Obesity and Cardiovascular Disease: An Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2026. Obesity Pillars, 20, 100283. https://doi.org/10.1016/j.obpill.2026.100283 (PMID 42729919)
    • Bays, H. E. (2011). Adiposopathy is “sick fat” a cardiovascular disease?. Journal of the American College of Cardiology, 57(25), 2461-2473. https://doi.org/10.1016/j.jacc.2011.02.038 (PMID 21679848)
    • Lincoff, A. M., Brown-Frandsen, K., Colhoun, H. M., Deanfield, J., Emerson, S. S., Esbjerg, S., et al. (2023). Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. New England Journal of Medicine, 389(24), 2221-2232. https://doi.org/10.1056/NEJMoa2307563 (PMID 37952131)
    • Kosiborod, M. N., Abildstrøm, S. Z., Borlaug, B. A., Butler, J., Rasmussen, S., Davies, M., et al. (2023). Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity. New England Journal of Medicine, 389(12), 1069-1084. https://doi.org/10.1056/NEJMoa2306963 (PMID 37622681)
    • Packer, M., Zile, M. R., Kramer, C. M., Baum, S. J., Litwin, S. E., Menon, V., et al. (2025). Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity. New England Journal of Medicine, 392(5), 427-437. https://doi.org/10.1056/NEJMoa2410027 (PMID 39555826)
    • Ross, R., Neeland, I. J., Yamashita, S., Shai, I., Seidell, J., Magni, P., et al. (2020). Waist circumference as a vital sign in clinical practice: a Consensus Statement from the IAS and ICCR Working Group on Visceral Obesity. Nature Reviews Endocrinology, 16(3), 177-189. https://doi.org/10.1038/s41574-019-0310-7 (PMID 32020062)
    • Rönnegård, A.-S., Nowak, C., Äng, B., & Ärnlöv, J. (2022). The association between short-term, chronic localized and chronic widespread pain and risk for cardiovascular disease in the UK Biobank. European Journal of Preventive Cardiology, 29(15), 1994-2002. https://doi.org/10.1093/eurjpc/zwac127 (PMID 35727954)
    • Araújo, J., Cai, J., & Stevens, J. (2019). Prevalence of Optimal Metabolic Health in American Adults: National Health and Nutrition Examination Survey 2009-2016. Metabolic Syndrome and Related Disorders, 17(1), 46-52. https://doi.org/10.1089/met.2018.0105 (PMID 30484738)
    • O’Hearn, M., Lauren, B. N., Wong, J. B., Kim, D. D., & Mozaffarian, D. (2022). Trends and Disparities in Cardiometabolic Health Among U.S. Adults, 1999-2018. Journal of the American College of Cardiology, 80(2), 138-151. https://doi.org/10.1016/j.jacc.2022.04.046 (PMID 35798448)
    • Collaboration, A. B. I., Fowkes, F. G. R., Murray, G. D., Butcher, I., Heald, C. L., Lee, R. J., et al. (2008). Ankle brachial index combined with Framingham Risk Score to predict cardiovascular events and mortality: a meta-analysis. JAMA, 300(2), 197-208. https://doi.org/10.1001/jama.300.2.197 (PMID 18612117)
    • Vlachopoulos, C., Aznaouridis, K., & Stefanadis, C. (2010). Prediction of cardiovascular events and all-cause mortality with arterial stiffness: a systematic review and meta-analysis. Journal of the American College of Cardiology, 55(13), 1318-1327. https://doi.org/10.1016/j.jacc.2009.10.061 (PMID 20338492)
    • Pearson, T. A., Mensah, G. A., Alexander, R. W., Anderson, J. L., Cannon, R. O., Criqui, M., et al. (2003). Markers of inflammation and cardiovascular disease: application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation, 107(3), 499-511. https://doi.org/10.1161/01.cir.0000052939.59093.45 (PMID 12551878)
    • Maser, R. E., Mitchell, B. D., Vinik, A. I., & Freeman, R. (2003). The association between cardiovascular autonomic neuropathy and mortality in individuals with diabetes: a meta-analysis. Diabetes Care, 26(6), 1895-1901. https://doi.org/10.2337/diacare.26.6.1895 (PMID 12766130)

    Related reading

  • Adult female using a medical weighing scale in a healthcare setting.

    Malnutrition in Obesity: Screening the Patient a BMI Hides

    Malnutrition in Obesity: Screening the Patient a BMI Hides

    Malnutrition in obesity is diagnosed at any BMI under the GLIM criteria, for example reduced muscle mass plus inflammation. The usual screens miss it: among older outpatients with a BMI of 25 or more, 58.8% of those malnourished passed the short-form screen.

    A patient can carry excess fat and still lack the muscle, protein and micronutrients that recovery depends on. The screens most practices use were never designed to see that combination.

    Malnutrition in obesity is a diagnosis the chart is built to miss. Every tool that opens the workup keys on weight loss and thinness, so the heavy patient sails through clean while sarcopenic wasting, active metaflammation and empty micronutrient stores go unrecorded.

    The Global Leadership Initiative on Malnutrition (GLIM) never required a low weight. Its 2019 consensus asks for one phenotypic criterion (non-volitional weight loss, low BMI or reduced muscle mass) plus one etiologic criterion (reduced intake or assimilation, or inflammation and disease burden). Reduced muscle mass with inflammation is a complete diagnosis at any BMI. The 2025 five-year update kept that structure, left the choice of muscle-mass method to the technology a site has, allowed clinical judgment to satisfy the inflammation criterion, and named malnutrition in obesity as one of its open priorities. The criteria were never the obstacle. The habit of reading BMI as a proxy for nourishment is.

    Why the usual screen clears the patient with obesity

    GLIM is a two-step process: screen, then assess. The failure sits in the first step. Among 264 geriatric outpatients with a BMI of 25 or more, GLIM-defined malnutrition was present in 30.3% and sarcopenic obesity in 15.9%. More than half of the malnourished patients, 58.8%, were not at risk on the Mini Nutritional Assessment Short Form, the screen that would have sent them on to assessment. Among the patients that short form cleared, malnutrition ran 42.9% in those with sarcopenic obesity against 18.7% in those without. Where sarcopenic obesity and malnutrition coexisted, the odds ratio for frailty was 5.11, independent of age and comorbidity.

    The pattern holds at higher weights. In adults with advanced knee osteoarthritis and a BMI of 35 or more, averaging a BMI of 42.4, 26.1% met GLIM criteria through low muscle mass on DXA plus elevated C-reactive protein, 26.1% had sarcopenic obesity, and 13% had both. These are the patients queued for joint replacement, and nothing in a weight-based intake flags them.

    Sarcopenic obesity is a muscle diagnosis, not a weight diagnosis

    The ESPEN and EASO consensus defines sarcopenic obesity as excess adiposity coexisting with low muscle mass or function. Screening begins with an elevated BMI or waist circumference plus suspicion of low muscle mass or function from risk factors, symptoms or a validated questionnaire. Diagnosis then runs in order: muscle function first, body composition second. Stage I carries no complications; Stage II carries complications linked to altered body composition or muscle dysfunction.

    The consensus traces the condition to sedentary metabolic change, adipose tissue derangement, comorbid disease and aging, and those pieces run as a chain. Inflamed, insulin-resistant adipose tissue is the first driver, keeping a low-grade inflammatory signal running through the whole body. Muscle is the second: pain and fatigue cut movement, unloaded muscle wastes, and the patient loses glucose-disposal capacity while fat mass holds or grows. The third driver is economic. A food supply engineered around acellular carbohydrates and industrial seed oils sells calories far more readily than protein and micronutrients, so stored fuel rises while structural stores fall, and the scale records only the first half of that trade. Muscle and fat distribution also track neurodegenerative risk, which is set out in how body fat distribution relates to dementia.

    The micronutrient layer follows inflammation

    Among the first 200 adults evaluated for bariatric surgery at a hospital in Turin, 85.5% had at least one micronutrient deficiency, led by vitamin D at 74.5%, folate at 33.5% and iron at 32%. C-reactive protein was above 5 mg/L in 65% of them. After adjustment, elevated CRP carried an odds ratio of 5.84 for B12 deficiency and 4.02 for folate deficiency. Inflammation is therefore doing two jobs in the same patient: it satisfies a GLIM etiologic criterion, and it predicts which stores are empty. A high-sensitivity CRP on the draw both supports the diagnosis and tells you where to look next.

    Why it matters in the operating room and on a GLP-1 prescription

    Obesity alone is not the surgical hazard; muscle loss inside obesity is. Across 27,057 craniotomies in the American College of Surgeons NSQIP database, a sarcopenic-obese phenotype built from BMI and serum albumin carried an odds ratio of 2.28 for 30-day mortality, while the obese-replete phenotype showed no mortality increase at 1.06. Among 2,908 UK Biobank participants who went on to major abdominal cancer surgery, the 100 with sarcopenic obesity had a hazard ratio of 6.44 for death at 30 days and 3.61 at 90 days, with 27% longer hospital stays and 83% longer intensive care stays, yet no significant excess of complications (odds ratio 0.79).

    That finding inverts the usual preoperative logic. These patients did not have more complications. They had less reserve to survive the ones they had. A complication audit will never surface them, a BMI will actively reassure you, and the obesity paradox is really a muscle story: fat with muscle behind it survived, fat without it did not. Only a measurement of muscle separates the two before the first incision.

    Weight-loss therapy opens a second road into the same phenotype. In twenty randomized trials with 15,782 participants whose body composition was measured by DXA or MRI, lean mass made up 25% to 39% of the weight lost on incretin agonists, 35.2% on semaglutide, and a comparable 26.2% with lifestyle intervention alone. Lifestyle plus resistance training had the smallest lean share, 17.5%. A chart tracking weight, A1c and blood pressure can improve on every line while a patient with marginal muscle crosses into sarcopenic obesity. Resistance training and adequate protein are the treatment, because loaded muscle is the tissue that keeps its claim on amino acids during an energy deficit; body composition monitoring is how anyone knows whether they worked.

    State the evidence tier plainly: this is consensus and observational data, not a randomized trial of GLIM-guided optimization. Trials isolate one disease and exclude the inflamed, multimorbid patient with obesity, so that patient will not be handed to you as a trial result. Measure the mechanism in the patient in front of you. The patient-facing version of the preoperative window is nutrition before surgery and what to measure.

    Who to screen and what a finding changes

    • Adults with obesity scheduled for elective joint, spine or abdominal surgery, screened alongside the glycemia work in preoperative diabetes screening before surgery.
    • Patients about to start incretin therapy, with a repeat once weight loss is established.
    • Older adults with an overweight or obese BMI who have slowed down, fallen or report new fatigue, whatever a short-form screen said.
    • Patients with persistently elevated CRP or a long history of restrictive dieting and regain.

    Write those triggers into your selection criteria and standing orders so the screen does not depend on whether a patient looks thin.

    Measura [Cardiometabolic and Autonomic Health Analysis] supplies the objective half of the workup; it does not diagnose or treat malnutrition. Bioimpedance body composition reports skeletal muscle mass, fat mass and segmental distribution, the body-composition step the sarcopenic obesity algorithm calls for after muscle function is tested in your office. Laboratory panels can place high-sensitivity CRP, ferritin, B12, zinc and red blood cell magnesium beside fasting insulin; vitamin D, folate and albumin come from blood work you order. Indirect calorimetry measures resting energy expenditure, which is interpretable only against the lean mass figure from the same visit and gives a protein and energy plan a measured denominator.

    A finding changes management in three ways. A GLIM diagnosis built on low muscle mass documents malnutrition in a chart that says obesity, which moves nutritional optimization ahead of the operating date. A lean-mass baseline before incretin therapy turns muscle preservation from advice into an endpoint with a retest date. And sarcopenic obesity in an older adult belongs in the fall-risk work already structured at the annual wellness visit, next to cognitive assessment and fall prevention. Unmeasured is unmanaged. The patient-facing version, for someone told they cannot be malnourished at their weight, is can you be overweight and malnourished.

    Frequently asked questions

    Can a patient with obesity meet GLIM criteria for malnutrition?

    A patient with obesity meets GLIM criteria when reduced muscle mass coexists with reduced intake or with inflammation and disease burden; low BMI is only one of three phenotypic options. The 2025 update leaves the muscle-mass method to the resources a site has. The parallel problem of fat distribution hiding behind a normal BMI is covered in visceral adiposity screening beyond BMI.

    Why not rely on a short nutrition screen in heavier patients?

    Short screens lean on weight loss and appetite, so they under-call patients who have not lost weight. In 264 older outpatients with a BMI of 25 or more, 58.8% of those with GLIM-defined malnutrition were not at risk on the short form. Pairing the screen with a body composition measurement closes that gap, and standing orders that make screening reproducible keep it closed.

    How much of the weight lost on incretin therapy is muscle?

    In pooled randomized trials using DXA or MRI, lean mass was 25% to 39% of the weight lost on incretin agonists, similar to lifestyle-only weight loss, and 17.5% when resistance training was added. The share varies between patients, so a baseline and a repeat measurement matter. Why energy expenditure should be measured rather than estimated in the same patients is laid out in measured versus estimated metabolic rate.

    Which micronutrients deserve attention when obesity comes with inflammation?

    Before bariatric surgery, vitamin D, folate and iron deficiencies were the most common in one Italian series, and an elevated CRP raised the odds of B12 and folate deficiency. In patients taking metformin, a serum B12 alone can mislead; the functional markers worth adding are described in metformin B12 deficiency screening.

    Does sarcopenic obesity belong in fall-risk screening?

    Sarcopenic obesity together with malnutrition raised the odds of frailty and of disability in instrumental activities of daily living in older adults with an elevated BMI. Low muscle mass and function belong in the fall-risk assessment, and vitamin D status sits in the same conversation, as discussed in vitamin D screening indications and falls risk.

    Put muscle on the preoperative checklist

    See how the Measura protocol adds body composition, nutrient laboratory panels and measured metabolic rate to a referral or standing-order workflow.

    4477 Woodson Rd, Suite 201, St. Louis, MO 63134. Monday to Friday, 9:00 a.m. to 5:00 p.m. Please do not send symptoms, diagnoses or images through a web form — a website form is not a secure medical channel. Send your name and number and we will call you back.

    References

    • Cederholm, T., Jensen, G. L., Correia, M. I. T. D., Gonzalez, M. C., Fukushima, R., Higashiguchi, T., et al. (2019). GLIM criteria for the diagnosis of malnutrition – A consensus report from the global clinical nutrition community. Clinical Nutrition, 38(1), 1-9. https://doi.org/10.1016/j.clnu.2018.08.002
    • Cederholm, T., Jensen, G. L., Correia, M. I. T. D., Gonzalez, M. C., Fukushima, R., Pisprasert, V., et al. (2025). The GLIM consensus approach to diagnosis of malnutrition: A 5-year update. Clinical Nutrition, 49, 11-20. https://doi.org/10.1016/j.clnu.2025.03.018
    • Donini, L. M., Busetto, L., Bischoff, S. C., Cederholm, T., Ballesteros-Pomar, M. D., Batsis, J. A., et al. (2022). Definition and diagnostic criteria for sarcopenic obesity: ESPEN and EASO consensus statement. Clinical Nutrition, 41(4), 990-1000. https://doi.org/10.1016/j.clnu.2021.11.014
    • Kayhan Kocak, F. O., Altın, Z., & Kızıltaş, A. (2026). Malnutrition by GLIM and its overlap with sarcopenic obesity in older adults with elevated body mass index: A retrospective cross-sectional study. Nutrition in Clinical Practice, 41(3), 799-810. https://doi.org/10.1002/ncp.70086
    • Vieira, F. T., Godziuk, K., Barazzoni, R., Batsis, J. A., Cederholm, T., Donini, L. M., et al. (2025). Hidden malnutrition in obesity and knee osteoarthritis: Assessment, overlap with sarcopenic obesity and health outcomes. Clinical Nutrition, 48, 111-120. https://doi.org/10.1016/j.clnu.2025.03.019
    • Pellegrini, M., Rahimi, F., Boschetti, S., Devecchi, A., De Francesco, A., Mancino, M. V., et al. (2021). Pre-operative micronutrient deficiencies in patients with severe obesity candidates for bariatric surgery. Journal of Endocrinological Investigation, 44(7), 1413-1423. https://doi.org/10.1007/s40618-020-01439-7
    • Roach, C. S., Wertheimer, B., Shah, K. H., Lu, V. M., Shah, A. H., & Komotar, R. J. (2026). Sarcopenic obesity and cachexia as nutritional risk phenotypes and histology-specific outcomes after intracranial tumor resection: a histology-stratified NSQIP analysis of 27,057 cases. Neurosurgical Review, 49(1). https://doi.org/10.1007/s10143-026-04450-3
    • Chou, W. K., Guidozzi, N., Giorgi, L., Salem, R., & Markar, S. R. (2026). Impact of sarcopenic obesity on outcomes following major abdominal cancer surgery: A population-based observational study. European Journal of Surgical Oncology, 52(4), 111505. https://doi.org/10.1016/j.ejso.2026.111505
    • Eisa, N., & Barood, O. (2026). Lean Mass Changes With Incretin Therapy Versus Lifestyle Intervention: A Systematic Review and Meta-Analysis of Randomised Controlled Trials. Diabetes, Obesity & Metabolism, 28(6), 4818-4827. https://doi.org/10.1111/dom.70666

    Related reading

  • Older woman concentrating while stacking blocks in a tower game.

    Remitted Depression and Cognitive Decline: A Screening Trigger

    Remitted Depression and Cognitive Decline: A Screening Trigger

    Remitted depression is a screening trigger for cognitive decline: in one cohort of older adults whose depression had lifted, about one in four developed dementia within five years. That history is a reason to set a standardized cognitive baseline and follow it.

    Remission ends the mood episode, not the cognitive risk. A randomized trial built to slow decline in this group shows why the history belongs on the screening list.

    Remitted depression and cognitive decline travel together in older adults, and most charts stop tracking cognition the day the mood improves. The PACt-MD trial in Toronto showed that a combined prefrontal intervention could slow cognitive decline in exactly this group, with the clearest effect in patients whose depression was in remission. Measura [Cardiometabolic and Autonomic Health Analysis] provides neither the brain stimulation nor the cognitive remediation used in the trial. The primary care lesson sits upstream of both: a history of late-life depression is a reason to establish a standardized cognitive assessment baseline and follow it.

    The risk that persists after remission

    A 2025 umbrella review and meta-analysis pooled 18 studies of depression with onset in later life, covering 901,762 participants and 7,595 incident dementia cases, and found a hazard ratio of 1.95 for all-cause dementia; depression assessed in midlife carried a hazard ratio of 1.56. Heterogeneity was substantial, and the authors note that part of the late-life signal may be early neurodegeneration presenting as mood change. Either reading argues for measurement, the case developed in pairing cognitive screening with the metabolic picture.

    Clinical cohorts show what that looks like. In a prospective study of 130 older adults with remitted major depression and 100 normal controls, 98 patients and 55 controls completed 5-year follow-up; among the patients, 28.6% had mild cognitive impairment and 25.5% developed dementia within 5 years, an approximate 3 times higher risk of subsequent cognitive decline. Slower information-processing speed and weaker memory at baseline predicted conversion. In a separate cohort of 185 adults with remitted late-life depression and 114 never-depressed controls followed an average of 5 years, the remitted group started with measurable impairment. Those whose first episode came at 60 or later performed worse across domains and declined faster in verbal skills and delayed memory. Age at first episode is a triage variable most charts never record. Stress physiology is part of that picture, and its daily timing is covered in how gut bacteria shape the stress rhythm.

    What the PACt-MD trial tested

    The trial ran at 5 academic hospitals in Toronto. It enrolled older adults with remitted major depression, with or without mild cognitive impairment, aged 65 and older, or mild cognitive impairment without depression, aged 60 and older. Of 486 who consented, 375 received at least one session; mean age was 72.2 years. The active arm combined cognitive remediation, structured computer-based exercises, with transcranial direct current stimulation targeting the prefrontal cortex, 5 days a week for 8 weeks, followed by twice-yearly 5-day boosters and daily at-home remediation. The comparison arm received sham versions of both. Participants were assessed yearly for 3 to 7 years, over a median follow-up of 48.3 months.

    What it found, and what it did not

    The active treatment slowed decline on the global cognitive composite, with an adjusted z score difference of 0.21 at month 60, and showed effects on executive function and verbal memory. It produced no meaningful acute improvement at month 2 (0.06), and its effect on progression to mild cognitive impairment or dementia was weak and not statistically significant, with a hazard ratio of 0.66. Benefit was larger in participants with remitted depression and in APOE ε4 noncarriers.

    Two secondary reports from the trial refine who responds. Among 246 participants with analyzable baseline MRI, cortical thickness moderated the treatment effect on global cognition, executive function and verbal memory. Among 143 participants in the active arm, a stronger stimulation-induced electric field in the left dorsolateral prefrontal cortex was associated with slower decline.

    The non-obvious result is the shape of the effect. An intervention that did nothing measurable at two months separated from sham years later. A single post-treatment score would have called it a failure. Prevention in cognition is visible only through standardized, repeated measurement, and the same is true of the decline a practice is trying to catch, which is how serial results are interpreted. The second point is where the benefit concentrated: in noncarriers of the strongest genetic risk variant, which places the modifiable portion in the terrain rather than the genotype. Protocols that demand years of sessions also favor patients well enough to attend them; the depressed older patient with diabetes, chronic pain and a long medication list is the one primary care actually holds, and the one who most needs measuring. The other changeable risks this patient carries are organized by visit in measuring modifiable dementia risk factors.

    Why depression and cognition share a terrain

    Two biological drivers link them. The first is prefrontal and executive network dysfunction, the circuit the trial targeted, which impairs processing speed and planning long after mood recovers. The second is systemic: an inflamed subgroup of depressed patients carries elevated inflammatory markers and insulin resistance, the same metaflammation that injures cerebral small vessels and impairs neuronal fuel supply. The third driver is social. Late-life depression clusters with bereavement, retirement, isolation and loneliness, each of which removes daily cognitive and social load. Treatment accordingly includes behavior with a physiological rationale: aerobic and resistance exercise improve insulin sensitivity and cerebral blood flow, and sustained social contact keeps the executive networks under demand. Insulin signaling inside the brain is one of those shared routes, traced in what brain tissue shows about insulin resistance.

    Who to screen and what to measure

    • Adults 65 and older with a documented history of major depression now in remission.
    • Any patient whose first depressive episode began at 60 or later.
    • Remitted depression with subjective memory or processing-speed complaints.
    • Remitted depression with central adiposity, insulin resistance or vascular risk factors.

    A cognitive assessment administered the same way each time provides the baseline and the serial comparison. Laboratory panels address reversible contributors to a low score, including vitamin B12 and a full thyroid panel, and the metabolic drivers, including fasting insulin and high-sensitivity C-reactive protein. Candidates for cognitive remediation or brain stimulation are referred to geriatric psychiatry or research programs; Measura’s role ends at identification and measurement.

    The annual wellness visit already screens for depression and reviews cognition, which makes it the natural place to flag a remitted history. Standing orders can start the cognitive and laboratory measurements when that flag is present, and selection criteria keep the trigger consistent across clinicians. Where gait or balance is also a concern, cognitive assessment and fall prevention describes the pairing.

    Frequently asked questions

    Does a patient whose depression is fully remitted still need cognitive follow-up?

    The cohort evidence says remission does not reset cognitive risk. Remitted older adults start with measurable impairment, and in one clinical cohort a quarter developed dementia within five years. A baseline and a repeat interval set by findings make a later complaint interpretable. The broader rationale for pairing a cognitive score with metabolic measurement is in cognitive screening in primary care with the metabolic picture.

    Why order inflammatory and metabolic labs for a mood history?

    Because a subgroup of depressed patients is biologically inflamed and insulin resistant, and those drivers also act on cerebral small vessels and neuronal fuel supply. Identifying that subgroup changes the metabolic conversation and may explain a cognitive trajectory that mood treatment alone does not. It also flags reversible contributors to a low score. How to find the inflamed subgroup is covered in inflammation and depression: identifying the inflamed subgroup.

    Which reversible contributors should be excluded before attributing a low score to neurodegeneration?

    Residual depressive symptoms, poor sleep, anticholinergic medication burden, thyroid dysfunction, uncorrected hearing loss and vitamin B12 deficiency all lower cognitive scores. A serum B12 inside the reference range does not exclude functional deficiency, so methylmalonic acid is worth ordering when the score and the history do not fit. Interpretation of that marker is explained in the methylmalonic acid test when B12 looks normal.

    Does insulin resistance matter in a depressed older patient without diabetes?

    It can matter a great deal, because insulin resistance develops years before glucose crosses a diagnostic threshold and it is associated with both depression and cognitive decline. Fasting insulin alongside glucose shows the compensating phase that an A1c result misses. The screening approach, developed for patients with chronic pain but applicable to this group, is in depression and insulin resistance screening.

    Should patients be referred for cognitive remediation with brain stimulation now?

    The protocol required intensive sessions, boosters and years of follow-up in academic centers, and access outside research programs is limited. Referral to geriatric psychiatry is reasonable for interested patients who fit the trial profile. What every practice can do today is identify the history and document a standardized baseline, so any future treatment effect or decline is visible. Why the first administration matters is in what a cognitive baseline is for.

    Turn a mood history into a baseline

    See how the Measura protocol adds standardized cognitive assessment and targeted laboratory measurement for patients flagged at the wellness visit.

    4477 Woodson Rd, Suite 201, St. Louis, MO 63134. Monday to Friday, 9:00 a.m. to 5:00 p.m. Please do not send symptoms, diagnoses or images through a web form — a website form is not a secure medical channel. Send your name and number and we will call you back.

    References

    • Rajji, T. K., Bowie, C. R., Herrmann, N., Pollock, B. G., Lanctôt, K. L., Kumar, S., et al., & PACt-MD Study Group. (2025). Slowing Cognitive Decline in Major Depressive Disorder and Mild Cognitive Impairment: A Randomized Clinical Trial. JAMA Psychiatry, 82(1), 12-21. https://doi.org/10.1001/jamapsychiatry.2024.3241
    • Brain, J., Alshahrani, M., Kafadar, A. H., Tang, E. Y., Burton, E., Greene, L., et al., & Stephan, B. C. (2025). Temporal dynamics in the association between depression and dementia: an umbrella review and meta-analysis. eClinicalMedicine, 84, 103266. https://doi.org/10.1016/j.eclinm.2025.103266
    • Lin, Y. J., Huang, M. F., Yeh, Y. C., & Chen, C. S. (2024). Predicting risk of dementia among the elderly with major depressive disorder in remission: A prospective study. International Journal of Geriatric Psychiatry, 39(2), e6065. https://doi.org/10.1002/gps.6065
    • Ly, M., Karim, H. T., Becker, J. T., Lopez, O. L., Anderson, S. J., Aizenstein, H. J., et al., & Butters, M. A. (2021). Late-life depression and increased risk of dementia: a longitudinal cohort study. Translational Psychiatry, 11(1), 147. https://doi.org/10.1038/s41398-021-01269-y
    • Ho, N. C. W., Zhukovsky, P., Rajji, T. K., Bowie, C. R., Brooks, H., Butters, M. A., et al., & PACt-MD Study Group. (2026). Brain Structures and Cognitive Decline: Moderation Analysis of the PACt-MD Randomized Clinical Trial of Brain Stimulation Plus Cognitive Remediation in Older Adults With Remitted Depression or Mild Cognitive Impairment. The American Journal of Geriatric Psychiatry, 34(8), 1005-1015. https://doi.org/10.1016/j.jagp.2026.04.008
    • Mirjalili, M., Brooks, H., Ma, C., Lee, A., Bikson, M., Voineskos, A. N., et al., & PACt-MD Study Group. (2025). Impact of Transcranial Direct Current Stimulation-Induced Electric Fields on Slowing Cognitive Decline in Older Adults With Mild Cognitive Impairment or Remitted Major Depressive Disorder: An Analysis of the PACt-MD Randomized Clinical Trial. Biological Psychiatry. https://doi.org/10.1016/j.biopsych.2025.09.020

    Related reading

  • Older man holding light dumbbells at home.

    Body Fat Distribution and Dementia Risk: Screening Beyond the Scale

    Body Fat Distribution and Dementia Risk: Screening Beyond the Scale

    Body fat distribution shifts dementia risk: among 412,691 UK Biobank adults, a central fat pattern and fat concentrated in the arms each predicted more neurodegenerative disease, and muscle strength predicted less.

    Where fat sits and how much muscle surrounds it predicted neurodegenerative disease in a very large cohort. Weight and body mass index could not have shown either pattern.

    Body fat distribution and dementia risk are linked more tightly than body mass index can show, and the scale in the hallway is built to miss it. In the UK Biobank, a central obesity pattern and a pattern of fat concentrated in the arms each predicted more neurodegenerative disease, muscle strength predicted less, and cardiovascular disease carried up to a third of those associations. For a practice already screening vascular and metabolic risk, the finding moves body composition from a weight-loss metric to a neurological risk marker. Measura [Cardiometabolic and Autonomic Health Analysis] measures the compartments involved with segmental body composition testing; interpretation stays with the treating physician.

    What the UK Biobank analysis actually measured

    Xu and colleagues analyzed 412,691 UK Biobank participants, mean age 56.0 years and 55.1% female, with no neurodegenerative disease at recruitment. Over an average follow-up of 9.1 years, 8,224 developed a neurodegenerative disease, including Alzheimer and Parkinson disease. To limit reverse causation from the weight loss that precedes diagnosis, follow-up began after a 5-year lag.

    The exposure is the detail worth noticing. Whole-body fat and muscle mass, and the same compartments in the arms, legs and trunk, were measured by segmental bioimpedance, alongside grip strength by hand dynamometer and heel bone density by ultrasound. Principal component analysis reduced those measures to patterns rather than single variables. None of the patterns can be reconstructed from height and weight, the same limit set out in screening visceral adiposity beyond BMI. A simpler bedside proxy for the same central pattern is a waist index adjusted for weight in hypertensive patients.

    The patterns that raised and lowered risk

    Patterns labeled central obesity and arm-dominant fat distribution were associated with a higher rate of neurodegenerative disease, with hazard ratios of 1.13 to 1.18. Patterns for muscle strength, bone density and leg-dominant fat distribution, among others, were associated with a lower rate, with hazard ratios ranging from 0.74 to 0.94. Among single components, high versus low grip strength carried a hazard ratio of 0.73. Estimates were comparable across polygenic risk, APOE genotype and family history strata, so the association is not confined to the genetically susceptible.

    In a subcohort of 40,790 participants with brain MRI, the central obesity, arm-dominant fat and muscle strength patterns tracked brain atrophy and cerebral small vessel disease in the same directions, which argues against a diagnosis-coding artifact and for recording a cognitive assessment beside the composition result. Composition is one of several changeable risks that can be charted, sorted in which dementia risk factors a visit can measure.

    The cardiovascular route, and the part it does not explain

    Mediation analysis attributed 35.3% of the central obesity association, 14.3% of the arm-dominant fat association and 10.7% of the muscle strength association to incident cardiovascular disease, with cerebrovascular disease the largest contributor at 8.9% to 28.9% across patterns. Roughly two-thirds of the central obesity signal therefore runs through something other than a diagnosed vascular event.

    The authors point to ectopic fat, impaired insulin signaling and proinflammatory cytokines. That is the two-driver picture in practice: vascular injury on one side, and on the other the insulin resistance and metaflammation from ectopic fat described in insulin resistance and dementia screening. A 2026 imaging study of cognitively normal midlife adults, average age 49.8 years, adds the brain end of the chain, with visceral fat correlating with amyloid PET burden (rho 0.36) in women and White participants and a higher visceral-to-subcutaneous ratio associated with cortical tau. That imaging is done elsewhere, but the depot it describes is the one body composition estimates. The third driver is behavioral and structural: sedentary work, a food supply built on acellular carbohydrate, and a visit that records weight because weight is what the scale in the hallway produces.

    Newer UK Biobank work: hips, metabolic treatment and muscle

    Three later UK Biobank studies sharpen the clinical reading. In 440,861 UK Biobank participants followed a median 12.7 years, waist circumference was positively associated with dementia, predominantly vascular dementia, but the association disappeared after adjustment for treatments for metabolic disorders, while larger hip circumference was protective, with a highest-versus-lowest quartile hazard ratio of 0.75 in women and 0.83 in men. The harm of central fat appears to travel through a metabolic state that is treatable, and the gluteofemoral depot behaves differently from the abdominal one.

    In 152,028 participants followed a median 14.1 years, carrying all three components of osteosarcopenic adiposity, low bone density, low muscle mass or grip strength and high body fat percentage, raised the hazard of Alzheimer-related dementia to 1.46, and optimal cardiovascular health attenuated that risk. In 190,406 participants, each 5-kg lower grip strength was associated with incident dementia at a hazard ratio of 1.20 in men and 1.12 in women.

    A 2026 meta-analysis of cohort studies resolves an apparent paradox. Late-life obesity looked protective against dementia (hazard ratio 0.83), while sarcopenia raised risk (hazard ratio 1.42). Weight in late life is confounded by the muscle and weight loss that precede diagnosis; composition separates what weight blends together, and balance testing catches the fall risk that muscle loss brings. Low muscle hidden under excess weight is its own screening problem, set out in malnutrition in patients with obesity.

    Who to measure, and what a finding changes

    Weight-based screening misclassifies two patients this literature cares about: the older adult whose stable weight hides muscle loss, and the normal-BMI South Asian or East Asian patient who is thin outside and fat inside, metabolically inflamed and insulin resistant at a body mass index that looks reassuring. Written selection criteria should name both.

    The limits belong in one sentence: these are observational cohorts of healthier-than-average volunteers with the patterns derived inside them, so a Measura result informs risk and follow-up rather than assigning a hazard ratio to an individual. The metabolically complicated patient is underrepresented in such cohorts, which is an argument for measuring that patient, not for waiting. Pairing the findings with cognition is set out in cognitive assessment and fall prevention.

    Frequently asked questions

    Why not rely on waist circumference?

    Waist circumference captures central adiposity but misses arm-dominant fat, muscle mass and strength, each of which carried independent signal in the UK Biobank patterns. It also cannot separate a protective hip and thigh depot from abdominal fat, and it misreads the thin-outside, fat-inside patient. Waist is a reasonable first step and a poor last one. The broader case against BMI-based screening is in visceral adiposity screening beyond BMI.

    Is late-life weight really protective against dementia?

    The pooled cohort data show lower dementia risk with late-life obesity but higher risk with midlife obesity and with sarcopenia. The likeliest explanation is reverse causation and confounding by muscle loss, since weight falls in the years before diagnosis. That is why the UK Biobank analysis used a lag period and why composition, not weight, is the useful measurement. Patient-facing framing is in body composition is not the same as weight.

    How does insulin resistance fit with the body composition findings?

    Cardiovascular disease explained at most about a third of the central obesity association, leaving ectopic fat and impaired insulin signaling as leading candidates for the rest. Insulin resistance is measurable years before glucose rises, so fasting insulin belongs beside the composition result in the same encounter. The screening argument for measuring the compensating years is developed in insulin resistance and dementia: screening past the glucose.

    Why add vascular testing when the outcome is neurological?

    Because cerebrovascular disease was the largest single mediator between body composition patterns and neurodegenerative disease, and vascular changes are measurable before an event. Arterial stiffness and endothelial function describe the vessel wall that transmits central adiposity’s effects to the brain’s small vessels. A finding there changes the intensity of vascular prevention. What the endothelial measurement shows is explained in what endothelial dysfunction testing reveals.

    Where do grip strength and balance fit in the workup?

    Lower grip strength predicted dementia in UK Biobank men and women, and low muscle mass travels with fall risk in the same older patients. Grip strength is quick to record at a visit, and balance testing adds the vestibular and central components of fall risk. Combining those with a cognitive baseline gives one coherent plan for a patient losing muscle. The fall side of that picture is covered in dizziness and the risk of falling.

    Measure composition, not just weight

    Learn how the Measura protocol adds segmental body composition, vascular and cognitive measurement to the risk screening your practice already performs.

    4477 Woodson Rd, Suite 201, St. Louis, MO 63134. Monday to Friday, 9:00 a.m. to 5:00 p.m. Please do not send symptoms, diagnoses or images through a web form — a website form is not a secure medical channel. Send your name and number and we will call you back.

    References

    • Xu, S., Wen, S., Yang, Y., He, J., Yang, H., Qu, Y., Zeng, Y., Zhu, J., Fang, F., & Song, H. (2024). Association Between Body Composition Patterns, Cardiovascular Disease, and Risk of Neurodegenerative Disease in the UK Biobank. Neurology, 103(4), e209659. https://doi.org/10.1212/WNL.0000000000209659
    • Liu, Z. Y., Qian, Y. W., Gu, J. M., Shao, X. P., Miao, M. Y., Lyu, J. Q., et al., & Chen, G. C. (2025). Association of Android and Gynoid Fatness With Incident Dementia and Brain Structure. Journal of Cachexia, Sarcopenia and Muscle, 16(5), e70095. https://doi.org/10.1002/jcsm.70095
    • Wang, W., Ren, R., Yang, H., Jiang, J., Ye, X., Wang, C., et al., & Wang, D. (2025). Healthy Cardiovascular Status Attenuates the Detrimental Association Between Osteosarcopenic Adiposity and Alzheimer’s Disease-Related Dementia: A UK Biobank Cohort Study. Journal of the American Heart Association, 14(11), e041697. https://doi.org/10.1161/JAHA.125.041697
    • Duchowny, K. A., Ackley, S. F., Brenowitz, W. D., Wang, J., Zimmerman, S. C., Caunca, M. R., & Glymour, M. M. (2022). Associations Between Handgrip Strength and Dementia Risk, Cognition, and Neuroimaging Outcomes in the UK Biobank Cohort Study. JAMA Network Open, 5(6), e2218314. https://doi.org/10.1001/jamanetworkopen.2022.18314
    • Booranasuksakul, U., Guan, Z., Radin Pereira, L., Tsintzas, K., Macdonald, I., Stirling, E., et al., & Siervo, M. (2026). Sarcopenia, obesity, sarcopenic obesity and dementia risk: a systematic review and meta-analysis of cohort studies. International Journal of Food Sciences and Nutrition, 1-16. https://doi.org/10.1080/09637486.2026.2722926
    • Dolatshahi, M., Commean, P. K., Naghashzadeh, M., Kassani, S. H., Rahmani, F., Xu, Y., et al., & Raji, C. A. (2026). Abdominal adiposity and Alzheimer’s disease imaging markers across sex and race at midlife. Journal of Alzheimer’s Disease, 112(2), 991-1003. https://doi.org/10.1177/13872877261455657

    Related reading

  • Older couple walking arm in arm along a city street.

    Modifiable Risk Factors for Dementia: What Primary Care Can Measure

    Modifiable Risk Factors for Dementia: What Primary Care Can Measure

    Primary care can measure four of the 14 modifiable dementia risk factors in the 2024 Lancet Commission with a number: blood pressure, glucose regulation, LDL cholesterol and adiposity. The others have to be asked about, and some were settled long before the visit.

    A population estimate of preventable dementia does not tell a clinician what to order. Sorting the risk factors by how they reach the chart does.

    Modifiable risk factors for dementia now number 14 in the 2024 Lancet Commission, which estimates that 45% of dementias worldwide are preventable if all 14 were eliminated. The standard visit measures perhaps four of them with a blood pressure cuff, a glucose and a lipid panel, and files the rest as yes-or-no history. That gap, not the list, is the primary care problem: which factors can be measured, which have to be asked about, and which were settled long before the patient reached the exam room. Measura [Cardiometabolic and Autonomic Health Analysis] addresses the measurable portion, from a standardized cognitive assessment baseline to the metabolic and vascular numbers behind it, and it helps to be exact about where that portion ends.

    The 14 factors, sorted by how they reach the chart

    The Commission’s list runs across the life course: less education early in life; hearing loss, high LDL cholesterol, depression, traumatic brain injury, physical inactivity, diabetes, smoking, hypertension, obesity and excessive alcohol use in midlife; and social isolation, air pollution and vision loss in late life. High LDL cholesterol and untreated vision loss were the additions in the 2024 report. For a clinic workflow they fall into three groups.

    • Measured with a number. Blood pressure, glucose regulation, LDL cholesterol and adiposity. This is where measurement can go past the default: fasting insulin beside glucose and hemoglobin A1c on laboratory panels, fat and muscle compartments on bioimpedance body composition instead of body mass index, and vessel wall behavior on arterial stiffness and endothelial function, which records what years of hypertension and hyperglycemia have done rather than today’s reading.
    • Screened with an instrument. Depression, hearing, vision, alcohol use and social isolation. Hearing and vision testing are done by audiology and eye care, not by Measura; validated questionnaires cover the rest.
    • Taken as history. Education, head injury and air pollution exposure. They cannot be changed at the visit, but they change how a borderline cognitive score should be read.

    What the attributable fractions look like in real cohorts

    The global figure pools very different populations, and cohort data narrow it. Norway’s HUNT study collected all 14 factors across adulthood in the same people and made its own dementia diagnoses in adults 70 and older. Among 9,745 participants, the authors concluded that addressing all 14 Lancet risk factors could prevent over half of all dementia cases.

    In the United States, the Dementia Risk Prediction Project pooled 37,931 participants across six longitudinal cohorts and split the question by age. Factors present in midlife, 45 to 64, accounted for 22.7% of dementia cases, and factors present in late life, 65 and older, for 16.5%. The largest single contributors were late-life physical inactivity at 10.4%, lower education at 8.1% and midlife obesity at 7.7%. Two of the top three are body and behavior, and one of them is measured poorly by weight.

    The vascular timeline is sharper. In the Atherosclerosis Risk in Communities study, with 33 years of follow-up in Black and White adults from four US communities, the share of dementia by age 80 attributable to at least one of hypertension, diabetes or current smoking was 21.8% when those factors were measured at 45 to 54 and 44.0% when they were measured at 65 to 74. After 80, only 2% to 8% of cases were attributable to them. The decade of the annual wellness visit is the decade in which measured vascular risk carries the most attributable dementia, and the window narrows quickly after it.

    One factor hides behind a normal eye chart. In a cross-sectional analysis of 2,767 older adults in the National Health and Aging Trends Study, a nationally representative sample of US Medicare beneficiaries, 19.0% of prevalent dementia was attributable to at least one objectively measured vision impairment, and contrast sensitivity impairment carried the largest share at 15.0%. A distance acuity chart does not test contrast sensitivity, so the patient who reads the bottom line can still carry the vision deficit most closely tied to dementia. Depression carries its own attributable share, and why remission does not close it is covered in remitted depression as a screening trigger.

    Why the measurable factors cluster in one patient

    Hypertension, diabetes, obesity, high LDL cholesterol and inactivity are usually charted as five problems. Biologically they converge on two. The first is insulin resistance, which starves insulin-dependent neurons of fuel and feeds the metaflammation that stiffens vessels. The second is the cerebral microvasculature itself, where a stiffened aorta delivers pulsatile pressure into small vessels built for steady flow. The third driver is social and economic: less schooling, food environments dominated by acellular carbohydrate and industrial seed oils, and isolation cluster in the same neighborhoods and the same patients. Metabolic health is already the exception: fewer than 12.2% of US adults qualified in NHANES 2009 to 2016, and the stricter post-2021 criteria put the share under 7%. Trials that test one factor at a time exclude this patient. The patient in the exam room carries five at once, which is why measuring the shared terrain beats counting diagnoses.

    A less obvious link sits in the traumatic brain injury item. In older adults, head injury is most often a fall, and falls follow balance, vision, orthostatic blood pressure and cognition together. Vestibular and balance testing therefore belongs in dementia prevention as much as in fall prevention. Where fat and muscle sit adds a further measurable layer, discussed in body composition patterns and neurodegenerative risk.

    Does changing the factors change cognition?

    The largest US test is the POINTER trial, which enrolled 2,111 adults aged 60 to 79 with a sedentary lifestyle and suboptimal diet plus other risk criteria at 5 US clinical sites. Both a structured and a self-guided lifestyle program raised global cognition over two years, and the structured program did so faster by 0.029 SD per year, with benefit in APOE ε4 carriers and noncarriers alike. The effect is modest, and a 2025 review argues that individual-level programs work within limits set by social and commercial determinants. The practice position is that lifestyle and behavior are treatment: exercise improves insulin sensitivity and cerebral blood flow, and structure, accountability and repeated measurement are what distinguished the stronger arm.

    Detection before symptoms is moving toward physiology

    Research is also pushing detection earlier. In 137 community-dwelling Black Americans aged 60 to 90 recruited through Wayne State University and the Michigan Alzheimer’s Disease Research Center, 84 cognitively healthy and 53 with mild cognitive impairment, a resting-state EEG connectivity model separated the groups with 91.97% leave-one-out cross-validation accuracy and predicted progression trends over 9 to 18 months with 84.61% accuracy in a limited subset. Measura does not perform EEG; that work remains in research settings. What a practice can do now is fix a standardized cognitive assessment as a baseline and repeat it under the same conditions. Before a slipping score is labeled dementia, a reversible liver cause is worth excluding, as described in liver fibrosis screening in patients with dementia.

    Workflow: turning the list into orders

    Most of the 14 already have a home in the annual wellness visit, which asks about depression, function and cognition. The gap is conversion of the measurable factors into measurements rather than yes-or-no history. Standing orders let staff start the metabolic, vascular and body composition measurements when a trigger is documented, and cognitive assessment and fall prevention describes pairing the cognitive baseline with balance findings. Documenting each factor as measured, screened or historical makes the risk profile legible to the next clinician.

    Frequently asked questions

    Does the 45% estimate mean that share of a practice’s dementia is preventable?

    It does not. The figure is a global population attributable fraction that assumes each association is causal and that exposure could be removed entirely. Cohort estimates range from about a fifth of cases in pooled US data by life stage to over half in Norway. Its clinical value is in pointing to which exposures deserve measurement and follow-up. The patient-facing version of that argument is dementia prevention starts with numbers you can measure now.

    Which of the 14 factors can be documented with objective measurement?

    Blood pressure, glucose regulation, LDL cholesterol and adiposity can be measured directly, and vascular consequences can be quantified with arterial stiffness testing. Hearing and vision require audiology and eye care, while depression, alcohol use and isolation rely on validated instruments. Recording which factors were measured rather than self-reported strengthens quality documentation, as described in quality measures that cardiometabolic testing supports.

    Why add metabolic measurement to a cognitive screen?

    Because a cognitive score records an outcome while the metabolic and vascular measurements describe the terrain producing it. A drifting score in a patient with central adiposity and insulin resistance supports a different follow-up plan than the same score in a metabolically healthy patient. Pairing them also sets up a repeat interval tied to findings. The case is developed in cognitive screening in primary care with the metabolic picture.

    How should LDL cholesterol be handled in a patient worried about statins and memory?

    High LDL cholesterol is now on the Commission’s list, and many patients have also read that statins affect memory. A documented cognitive baseline before or early in lipid therapy turns a later complaint into a comparison rather than a guess, and keeps the lipid decision with the treating physician. The measurement protocol for patients on statins is described in statins and dementia: measuring cognition in patients on statins.

    Should EEG-based detection change practice now?

    Not yet at the point of care. The resting-state EEG model performed well in a modest sample with a limited progression subset, and it needs replication before it guides individual decisions. The transferable lesson is the value of a physiological measurement repeated over time, which a standardized cognitive screen already provides in a primary care setting. Why the first administration matters most is explained in what a cognitive baseline is for.

    Put the measurable risk factors on paper

    See how the Measura protocol turns the metabolic, vascular, body composition and cognitive items on the dementia risk list into documented measurements inside your existing visits.

    4477 Woodson Rd, Suite 201, St. Louis, MO 63134. Monday to Friday, 9:00 a.m. to 5:00 p.m. Please do not send symptoms, diagnoses or images through a web form — a website form is not a secure medical channel. Send your name and number and we will call you back.

    References

    • Livingston, G., Huntley, J., Liu, K. Y., Costafreda, S. G., Selbæk, G., Alladi, S., et al., & Mukadam, N. (2024). Dementia prevention, intervention, and care: 2024 report of the Lancet standing Commission. The Lancet, 404(10452), 572-628. https://doi.org/10.1016/S0140-6736(24)01296-0
    • Ma’u, E., Cullum, S., Röhr, S., & Brayne, E. C. (2025). Are modifiable risk factors for dementia really modifiable? Current Opinion in Psychiatry, 38(5), 348-354. https://doi.org/10.1097/YCO.0000000000001018
    • Ellingjord-Dale, M., Strand, B. H., Skirbekk, V., Bratsberg, B., Mekonnen, T., Zotcheva, E., et al., & Engdahl, B. (2025). Potentially modifiable risk factors for dementia in Norway (HUNT4 70+): a retrospective cohort study. The Lancet Healthy Longevity, 6(12), 100802. https://doi.org/10.1016/j.lanhl.2025.100802
    • Li, J. M., Gauen, A. M., Zmora, R., Stephen, J. J., Petito, L. C., Scholtens, D., et al., & Allen, N. B. (2026). Midlife and late-life population attributable fractions of risk factors for dementia in the United States: The Dementia Risk Prediction Project. Alzheimer’s & Dementia, 22(1), e71065. https://doi.org/10.1002/alz.71065
    • Smith, J. R., Pike, J. R., Gottesman, R. F., Knopman, D. S., Lutsey, P. L., Palta, P., et al., & Deal, J. A. (2025). Contribution of Modifiable Midlife and Late-Life Vascular Risk Factors to Incident Dementia. JAMA Neurology, 82(7), 644-654. https://doi.org/10.1001/jamaneurol.2025.1495
    • Smith, J. R., Huang, A. R., Zhou, Y., Varadaraj, V., Swenor, B. K., Whitson, H. E., et al., & Ehrlich, J. R. (2024). Vision Impairment and the Population Attributable Fraction of Dementia in Older Adults. JAMA Ophthalmology, 142(10), 900-908. https://doi.org/10.1001/jamaophthalmol.2024.3131
    • Baker, L. D., Espeland, M. A., Whitmer, R. A., Snyder, H. M., Leng, X., Lovato, L., et al., & Carrillo, M. C. (2025). Structured vs Self-Guided Multidomain Lifestyle Interventions for Global Cognitive Function: The US POINTER Randomized Clinical Trial. JAMA, 334(8), 681-691. https://doi.org/10.1001/jama.2025.12923
    • Deng, J., Sun, B., Kavcic, V., Liu, M., Giordani, B., & Li, T. (2024). Novel methodology for detection and prediction of mild cognitive impairment using resting-state EEG. Alzheimer’s & Dementia, 20(1), 145-158. https://doi.org/10.1002/alz.13411

    Related reading

  • Older man walking with a cane along a tree-lined park path.

    Metabolic Osteoarthritis: Screening the Hand and Younger Joint

    Metabolic Osteoarthritis: Screening the Hand and Younger Joint

    Metabolic osteoarthritis screening belongs in two presentations: osteoarthritis in the finger joints, which carry almost no load, and osteoarthritis that starts unexpectedly young. In both, a glycemic, insulin and lipid panel is the right first test.

    Load explains the knee. It does not explain the interphalangeal joint, and it does not explain a fifty-year-old with four affected sites. Those two presentations are the screening trigger.

    Metabolic screening in osteoarthritis is usually skipped for a reason that sounds like physiology: the joint hurts because it carries weight. That reasoning holds at the knee and collapses in the hand. The distal and proximal interphalangeal joints carry essentially nothing, and they are where the systemic signal separates most cleanly from the load signal. So does age at onset. Those two presentations, the inflamed hand and the unexpectedly young joint, are where a referral for a brace and an analgesic is answering the wrong question, and a glycemic, insulin and lipid panel is the right first one.

    What the adjusted data support, and what they do not

    Be precise, because this literature is overstated in both directions. Diabetes and osteoarthritis travel together: a meta-analysis of 49 studies put the odds of osteoarthritis in diabetes at 1.46, with an average osteoarthritis prevalence of 29.5% among 5788 patients with diabetes. Of the 12 included studies that adjusted for body mass index, 7 kept diabetes as an independent risk factor and 5 did not. That split is the honest state of the field.

    Adiposity carries the strongest causal signal. In a Swedish general-population cohort of 10,633 adults with no osteoarthritis diagnosis and no joint pain at baseline, metabolic syndrome carried a hazard of 1.17 for incident osteoarthritis in any joint. Elevated waist circumference alone carried 1.42, and metabolic syndrome without an elevated waist carried 1.02, which is nothing. Across 271,019 participants from the UK Biobank and the National Health and Nutrition Examination Survey, with Mendelian randomization alongside, metabolic syndrome was not an independent risk factor once body mass index was accounted for, risk began climbing around a body mass index of 27, and waist circumference was the component that mattered, the argument behind screening visceral adiposity beyond BMI.

    The loading model is not wrong; it is incomplete, and the genetics say so. A cross-trait analysis found a genetic correlation between metabolic syndrome and osteoarthritis of 0.393, with Mendelian randomization supporting liability to metabolic syndrome raising osteoarthritis risk and no reverse effect. Staging the whole cardiometabolic picture sharpens it further. Among 256,364 UK Biobank participants without osteoarthritis at baseline, the most advanced cardiovascular-kidney-metabolic stage carried hazards of 1.76 for hip and 2.67 for knee osteoarthritis against stage 0, and the associations were stronger in younger participants.

    The hand is the phenotype that survives adjustment

    This is the finding that should change a referral note. In 952 women aged 45 to 65 from the Chingford cohort, metabolic syndrome was associated with painful knee osteoarthritis until body mass index entered the model, at which point it vanished. The association with painful interphalangeal osteoarthritis survived adjustment for both age and body mass index, and four of the five syndrome components tracked with it. Weight itself is associated with hand osteoarthritis: a systematic review of 25 studies graded the evidence moderate with an approximate risk ratio of 1.9, which load cannot explain in a joint that bears no body weight; the same logic already makes carpal tunnel a diabetes screening trigger. In a dedicated hand osteoarthritis cohort, metabolic syndrome went with more pain independent of structural damage and of anxiety and depression scores.

    Two biological drivers account for that. Adipose tissue is an endocrine organ, and the metaflammation it generates, adipokines and cytokines, reaches cartilage in the finger as readily as cartilage in the knee. Hyperglycemia acts on the tissue itself, through glycation and oxidative stress in a matrix that turns over slowly. The third driver is structural: osteoarthritis is coded, referred and treated as a mechanical diagnosis, so the patient goes to physical therapy or an injector and nobody is assigned the terrain. Dr. Padda admits to years of closing visits by telling patients with a borderline A1c that the number could wait. A hand radiograph in that patient is a second chance to stop saying it. Periodontal inflammation is another tissue signal that runs ahead of a metabolic diagnosis, set out in sugar, gum inflammation and what to measure.

    What a finding changes in management

    Three things, and none is a new drug.

    First, the weight conversation becomes a measured intervention with a comparator rather than a handout. In a 68-week randomized trial of 407 adults with obesity and moderate knee osteoarthritis, once-weekly semaglutide produced a mean weight change of -13.7% against -3.2% on placebo, with pain scores falling -41.7 points against -27.5. That is what treating adiposity as the driver can do.

    Second, body composition changes the target. A meta-analysis of 12 studies found low muscle mass index associated with knee osteoarthritis at 1.36 and sarcopenic obesity at 1.78, on low-quality evidence. A patient who loses weight and keeps losing muscle has not improved, and only measured body composition shows it. Loading and protein intake are treatment, each with its physiological rationale documented.

    Third, fall risk enters the plan. Across 17 studies and 862,849 participants, symptomatic knee osteoarthritis carried 1.55 times the odds of recurrent falls. In an older patient with knee pain, sarcopenic obesity and unsteadiness, the joint diagnosis and the fall risk are one problem.

    None of this argues against the injection. A joint injection is the bridge: it controls pain now so the patient can load the joint, sleep and do the metabolic work. The failure mode is a bridge with nothing on the other side, and the metabolic panel is how the other side gets built. Patients who ache in several joints at once often carry the visceral pattern described in the MRI evidence linking belly fat to chronic pain.

    Who to test

    • Any patient with hand osteoarthritis, particularly interphalangeal involvement with pain out of proportion to radiographic grade.
    • Osteoarthritis at an age or in a joint distribution that load does not explain, including multi-joint disease before the sixth decade.
    • Patients whose waist circumference is above target regardless of body mass index category.
    • Patients with diabetes or an A1c in the prediabetic band being referred for injection, physical therapy or arthroplasty evaluation.
    • Older patients with knee or hip osteoarthritis who report unsteadiness, a near-fall or a fall.
    • Patients told to lose weight at several visits in a row without any measured change being recorded.

    Written selection criteria keep that list consistent across clinicians. For patients already scheduled for joint replacement, the preoperative window is covered in what to have measured before surgery.

    What Measura measures in this pathway

    Measura [Cardiometabolic and Autonomic Health Analysis] is a testing service. It performs no injections, no imaging and no treatment; radiographs and joint imaging are done elsewhere, and findings return to the ordering physician. Three measurements apply:

    None of these measures cartilage, and no metabolic result diagnoses or grades osteoarthritis. What they supply is the phenotype the radiograph cannot show.

    Building it into the referral

    Attach the panel to the diagnosis rather than to the encounter. A standing order that triggers metabolic labs and body composition on a new hand osteoarthritis diagnosis, or on any osteoarthritis diagnosis under sixty, is the version that survives a busy clinic. Recorded at the annual wellness visit, where fall risk and cognition are already structured, the results support the cardiometabolic documentation those visits capture, as documentation rather than as an indication in itself. The same reasoning for tendon disease is in tendinopathy as a metabolic signal, and the pre-procedure version is in metabolic screening before repeat joint injections.

    The limits, stated once: almost all of this is observational, most of the metabolic syndrome signal in weight-bearing joints is adiposity rather than the syndrome, and reverse causation is possible where pain limits activity. Trials that could settle causation enroll one disease at a time and screen out the patient with obesity, diabetes, depression and three painful joints, who is the patient actually in the exam room. The hand data and the genetic data keep the systemic reading alive, and the practice position follows from them. Measure the terrain in the patient whose joints cannot be explained by what they carry, then measure it again to see whether it moved.

    Frequently asked questions

    Is metabolic syndrome an independent risk factor for knee osteoarthritis?

    Largely not, once adiposity is accounted for. In a Swedish incident-osteoarthritis cohort the hazard was 1.17 for metabolic syndrome but 1.02 without an elevated waist, and a 271,019-participant analysis found no independent effect after body mass index adjustment. Waist circumference carried the signal. The clinical implication is to measure adiposity properly rather than to score the syndrome. The metaflammation screening logic is the same.

    Why does hand osteoarthritis justify metabolic testing?

    Because interphalangeal joints bear no body weight, so an association with weight and with metabolic syndrome cannot be explained by load. In the Chingford cohort the association with painful interphalangeal disease survived adjustment for age and body mass index while the knee association did not, and weight tracked hand osteoarthritis at a risk ratio near 1.9 across 25 studies. That is a systemic phenotype presenting in a small joint. The same load-independent reading applied to tendons is covered in insulin resistance and tendon pain.

    What does body composition add to a body mass index already in the chart?

    The fat and lean compartments separately. Low muscle mass index was associated with knee osteoarthritis at 1.36 and sarcopenic obesity at 1.78 in pooled analysis, and both are invisible in a single ratio. It also changes what success looks like during weight loss, since a patient losing lean mass alongside fat accumulates fall risk while the chart records improvement. Body composition is not the same as weight sets out the distinction.

    Where does fall prevention fit an osteoarthritis visit?

    Earlier than most plans put it. Symptomatic knee osteoarthritis carried 1.55 times the odds of recurrent falls across 17 studies and 862,849 participants, and lower-limb pain, sarcopenic obesity and unsteadiness commonly arrive together. Measuring balance in that patient turns a vague concern into a documented finding the care plan can act on. Orthostatic blood pressure in older adults covers a second contributor.

    Add the terrain to the joint diagnosis

    Learn how the Measura protocol attaches metabolic laboratory work, body composition and balance testing to osteoarthritis diagnoses, with results returned to the ordering physician.

    4477 Woodson Rd, Suite 201, St. Louis, MO 63134. Monday to Friday, 9:00 a.m. to 5:00 p.m. Please do not send symptoms, diagnoses or images through a web form — a website form is not a secure medical channel. Send your name and number and we will call you back.

    References

    • Louati, K., Vidal, C., Berenbaum, F., & Sellam, J. (2015). Association between diabetes mellitus and osteoarthritis: systematic literature review and meta-analysis. RMD Open, 1(1), e000077. https://doi.org/10.1136/rmdopen-2015-000077
    • Yusuf, E., Nelissen, R. G., Ioan-Facsinay, A., Stojanovic-Susulic, V., DeGroot, J., van Osch, G., Middeldorp, S., Huizinga, T. W., & Kloppenburg, M. (2010). Association between weight or body mass index and hand osteoarthritis: a systematic review. Annals of the Rheumatic Diseases, 69(4), 761-765. https://doi.org/10.1136/ard.2008.106930
    • Sanchez-Santos, M. T., Judge, A., Gulati, M., Spector, T. D., Hart, D. J., Newton, J. L., Arden, N. K., & Kluzek, S. (2019). Association of metabolic syndrome with knee and hand osteoarthritis: A community-based study of women. Seminars in Arthritis and Rheumatism, 48(5), 791-798. https://doi.org/10.1016/j.semarthrit.2018.07.007
    • Charton, A., Lacoste-Badie, R., Tuffet, S., Rousseau, A., Maheu, E., Fautrel, B., Dougados, M., Berenbaum, F., Courties, A., & Sellam, J. (2025). Metabolic syndrome is associated with more pain in hand osteoarthritis: Results from the DIGICOD cohort. Osteoarthritis and Cartilage Open, 7(1), 100573. https://doi.org/10.1016/j.ocarto.2025.100573
    • Andrea, D., Karin, M., Johanna, V., Stefan, L. L., Martin, E., & Ali, K. (2026). The role of metabolic syndrome in osteoarthritis development: Is obesity the key driver? Osteoarthritis and Cartilage Open, 8(1), 100739. https://doi.org/10.1016/j.ocarto.2025.100739
    • Wang, J., Peng, L., Xu, P., Guo, F., Xu, X., Wang, J., Yu, H., Xu, K., Yang, Z., Guo, J., & Yang, M. (2025). Unraveling the connection between obesity, metabolic syndrome and osteoarthritis risk: a large-observational study. Diabetology & Metabolic Syndrome, 18(1), 27. https://doi.org/10.1186/s13098-025-02059-y
    • Huang, J. X., Xu, S. Z., Tian, T., Wang, J., Jiang, L. Q., He, T., Meng, S. Y., Ni, J., & Pan, H. F. (2025). Genetic Links Between Metabolic Syndrome and Osteoarthritis: Insights From Cross-Trait Analysis. The Journal of Clinical Endocrinology and Metabolism, 110(2), e461-e469. https://doi.org/10.1210/clinem/dgae169
    • Ma, Z., Zhang, Y., Li, L., Zheng, G., Yang, H., Zhang, R., Li, Y., Wang, W., Ji, C., Xia, Y., & Zhao, Y. (2026). Association of cardiovascular-kidney-metabolic syndrome with risk of hip/knee osteoarthritis: A prospective cohort study. Maturitas, 212, 109056. https://doi.org/10.1016/j.maturitas.2026.109056
    • Bliddal, H., Bays, H., Czernichow, S., Udden Hemmingsson, J., Hjelmesaeth, J., Hoffmann Morville, T., Koroleva, A., Skov Neergaard, J., Velez Sanchez, P., Wharton, S., Wizert, A., & Kristensen, L. E. (2024). Once-Weekly Semaglutide in Persons with Obesity and Knee Osteoarthritis. The New England Journal of Medicine, 391(17), 1573-1583. https://doi.org/10.1056/NEJMoa2403664
    • Wu, Q., Xu, Z., Ma, X., Li, J., Du, J., Ji, J., Ling, X., Kan, J., & Zhao, M. (2024). Association of low muscle mass index and sarcopenic obesity with knee osteoarthritis: a systematic review and meta-analysis. Journal of the International Society of Sports Nutrition, 21(1), 2352393. https://doi.org/10.1080/15502783.2024.2352393
    • Zhang, Y., Li, X., Wang, Y., Ge, L., Pan, F., Winzenberg, T., & Cai, G. (2023). Association of knee and hip osteoarthritis with the risk of falls and fractures: a systematic review and meta-analysis. Arthritis Research & Therapy, 25(1), 184. https://doi.org/10.1186/s13075-023-03179-4

    Related reading

  • Two clinicians reviewing a patient folder in a hospital corridor.

    Screening for Cirrhosis in Dementia: The Encephalopathy in the Chart

    Screening for Cirrhosis in Dementia: The Encephalopathy in the Chart

    Screening for cirrhosis in dementia means computing a FIB-4 index from values already in the chart. In two national cohorts, 5% to 13% of patients with dementia had scores pointing to undiagnosed advanced fibrosis or cirrhosis, and hepatic encephalopathy, unlike most dementia, responds to treatment.

    A dementia diagnosis ends most cognitive workups. In a meaningful share of patients, routine laboratory values point to a liver that nobody has examined.

    Screening for cirrhosis in dementia is not routine, and two national cohorts show it has to be. Hepatic encephalopathy produces confusion, slowed thinking, sleep reversal and personality change, the same features that earn an older adult a dementia label, and unlike most dementia it responds to treatment. When cirrhosis has never been diagnosed, nobody asks, and a scored cognitive assessment gets read as proof of decline rather than a baseline that could improve. A FIB-4 index computed from values already in the chart asks the question, and a positive answer reopens a workup the diagnosis had quietly closed.

    What the veteran and TriNetX cohorts found

    Bajaj and colleagues examined Veterans Health Administration records from 2009 to 2019 for 177,422 US veterans with a dementia diagnosis at two or more visits, no prior cirrhosis diagnosis and enough laboratory data to calculate FIB-4. The cohort was 97.1% men with a mean age of 78.35 years, and FIB-4 was capped at age 65 in the calculation.

    • 5.3% (9,373) had FIB-4 above 3.25, the threshold suggestive of cirrhosis.
    • 10.3% (18,390) had FIB-4 above 2.67, suggestive of advanced fibrosis.
    • A local validation cohort of patients with dementia showed high FIB-4 in 4.4% to 11.2%.
    • FIB-4 above 3.25 was associated with viral hepatitis (odds ratio 1.79) and congestive heart failure (1.48), and inversely associated with diabetes (0.78).

    Veterans are overwhelmingly male, so the group repeated the analysis in the multi-center TriNetX network: 68,807 patients with dementia and no cirrhosis diagnosis, 44.7% male, mean age 72.73 years. FIB-4 exceeded 3.25 in 7.6% (5,815) and 2.67 in 12.8% (8,683). Congestive heart failure (odds ratio 1.73) again rose with high scores and diabetes (0.82) again ran inverse. The authors concluded that FIB-4 could be used to screen for potential undiagnosed cirrhosis in patients with dementia. Across both cohorts, somewhere between one in twenty and one in eight patients carrying a dementia diagnosis had a laboratory signature demanding a liver workup that nobody had ordered. The case for liver screening despite normal enzymes is in MASLD screening in primary care.

    Reading FIB-4 in the oldest patients

    Age is a multiplier in the formula, so the index behaves differently in a memory clinic than in the populations that validated it. In a biopsy cohort from European specialist hepatology clinics, specificity of FIB-4 for advanced fibrosis fell with age and was 35% in those aged 65 and older (n=76). A cut-off of 2.0 in that age group restored specificity to 70% with a sensitivity of 77%. That is why the veteran analysis capped age at 65 years even for those above this cutoff. An uncapped calculator run across a dementia panel overcalls, and overcalling is how a useful screen gets abandoned.

    Three confounders belong in the note. Congestive hepatopathy raises FIB-4 through the liver, and both cohorts found heart failure among its strongest associations, so a high value in heart failure is a reason to look at both organs, not to dismiss either. Platelet counts fall for reasons other than portal hypertension, including marrow disease and medication, so read them against the full laboratory panel. And the inverse association with diabetes runs against the metabolic expectation; a retrospective design cannot explain it, and it is no reason to skip patients with diabetes, whose fatty liver is the commonest road to cirrhosis in a metabolic practice. A plain-language version for patients holding their own score is what a fatty liver fibrosis score means.

    Why covert encephalopathy goes unrecognized

    Covert hepatic encephalopathy has no asterixis and no overt confusion. It lives in attention, processing speed and executive function, the exact domains that dementia screening reads as decline. At 16 medical centers across China, 528 patients with cirrhosis underwent psychometric and Stroop testing, and the prevalence of covert encephalopathy was 50.4%. Among cirrhotic patients referred to a dedicated clinic for cognitive complaints and given a full neuropsychological, EEG and MRI workup, about two thirds had covert encephalopathy; 73% of those also had another cause of impairment, most often cerebrovascular or psychiatric, and clinical improvement was observed in 77% of the patients re-evaluated after specific management. A second diagnosis does not cancel the treatable one.

    Liver disease short of cirrhosis already shows up on cognitive testing. In 69 outpatients with fatty liver disease, mean age 50.4 years, 32% scored below a Montreal Cognitive Assessment of 26 and 12% had encephalopathy detected on the EncephalApp test. Genetic evidence points the same way: in a two-sample Mendelian randomization analysis, genetically predicted liver fibrosis and cirrhosis carried an odds ratio of 1.849 for vascular dementia.

    The cascade runs through three drivers. First, gut-derived ammonia and bacterial products reach the brain once a scarred liver and portosystemic shunting stop filtering them; the first brain, the gut, becomes the source of the second brain’s toxin load. Second, skeletal muscle is the backup clearance route for ammonia, so sarcopenic wasting in an older patient removes the reserve at the moment the liver fails, which is why measured muscle mass belongs in this workup. Third, and most preventable, is the system: once a chart says dementia, every later cognitive change is pre-explained, alcohol use and isolation in older adults go unasked, and the liver panel is filed instead of calculated. The diagnosis becomes the reason nobody looks.

    What a positive screen changes

    A high FIB-4 in a patient with dementia is a referral trigger, not a diagnosis. Confirming fibrosis with elastography, staging cirrhosis and diagnosing encephalopathy belong to hepatology and imaging services. What changes in primary care is the frame, because hepatic encephalopathy is treatable. At 11 teaching hospitals in China, 98 cirrhotic patients with minimal encephalopathy were randomized to lactulose or no therapy, and at day 60 the reversal rate was 64.18% with lactulose against 22.58% without, a number needed to treat of 2.4. The 2014 joint American and European guideline builds management around correcting precipitants: sedatives, opioids, dehydration, infection and constipation.

    A positive screen also demands cognitive testing that is repeated rather than recorded once. If the score improves after encephalopathy treatment, the dementia label was at least partly wrong; if it does not, the patient has lost nothing but an unexamined assumption. Nutrition becomes treatment with a mechanism: adequate protein and muscle loading rebuild the ammonia-clearing capacity the liver has lost. The broader metabolic reading of a slipping cognitive score is in cognitive screening in primary care: add the metabolic picture. Hepatic encephalopathy belongs on the same differential as the changeable dementia risks sorted in turning dementia risk factors into orders.

    Where the measurements fit

    Measura [Cardiometabolic and Autonomic Health Analysis] is a testing service. It does not diagnose cirrhosis or hepatic encephalopathy, and it does not treat. It supplies the measurements:

    • Cognitive assessment establishes a scored baseline that can be repeated after hepatology review or treatment, turning a diagnostic assumption into a measured change.
    • Laboratory panels include hepatic panel groups selected to the clinical question; the ordering physician can confirm that AST, ALT and a platelet count are drawn together so FIB-4 can be calculated in the chart.
    • Bioimpedance body composition quantifies muscle mass, the second ammonia-clearance organ and a fall risk in its own right.

    Building the screen into standing orders

    The screen survives only when it is automatic. A rule in standing orders can require FIB-4 calculation, age capped or age-adjusted, whenever a dementia or mild cognitive impairment diagnosis is added and liver chemistry and a platelet count are on file. The annual wellness visit already requires cognitive assessment; recording the FIB-4 result and any referral beside it keeps the finding visible (see annual wellness visit integration), and pairing it with fall screening follows the structure in cognitive assessment and fall prevention. Unmeasured is unmanaged, and a reversible encephalopathy filed as dementia is the most expensive thing never measured.

    Frequently asked questions

    Which FIB-4 threshold should be used for patients over 65?

    Standard cut-offs lose specificity with age. In a biopsy cohort, a threshold of 2.0 in patients aged 65 and older improved specificity to 70% while keeping sensitivity at 77%. The dementia cohorts instead capped age at 65 in the formula and used 2.67 and 3.25. Either approach is defensible if it is written down and applied consistently. Why a documented baseline matters for later comparison is covered in cognitive screening: what a baseline is for.

    Does a high FIB-4 mean the dementia diagnosis is wrong?

    It means the diagnosis is incomplete until the liver is evaluated. Covert encephalopathy frequently coexists with vascular and neurodegenerative disease, so improvement after treatment may be partial. The aim is to find every reversible contributor, the same logic that applies to vitamin B12 and homocysteine in cognitive decline, discussed in B vitamins in mild cognitive impairment.

    How does hepatic encephalopathy differ from delirium in an older patient?

    Overt encephalopathy can look exactly like delirium and is precipitated by the same triggers: infection, dehydration, constipation and sedating drugs. Covert encephalopathy is subtler and persistent, affecting attention and processing speed without an acute change in consciousness. Untreated pain is another reversible driver of confusion that gets sedated rather than examined, as covered in delirium in elderly patients: rule out pain before sedation.

    Should patients with fatty liver and insulin resistance get cognitive testing?

    Cognitive deficits were common even in younger outpatients with fatty liver disease. A baseline cognitive score in a patient with MASLD, diabetes or central adiposity takes one visit and gives every later result a reference point. The metabolic side of that screening decision is laid out in insulin resistance and dementia: screening past the glucose.

    Which medications deserve review when cirrhosis is suspected in a patient with dementia?

    Sedative-hypnotics, opioids, anticholinergic drugs and anything that causes constipation or dehydration can precipitate or deepen hepatic encephalopathy, and hepatic clearance of many drugs falls in cirrhosis. A structured medication review belongs in the same encounter as the referral, anchored to measured function rather than a list, as argued in deprescribing starts with a baseline, not a drug list.

    Make the liver question routine

    Learn how the Measura protocol pairs repeatable cognitive assessment with laboratory and body composition data, and how it fits your standing orders.

    4477 Woodson Rd, Suite 201, St. Louis, MO 63134. Monday to Friday, 9:00 a.m. to 5:00 p.m. Please do not send symptoms, diagnoses or images through a web form — a website form is not a secure medical channel. Send your name and number and we will call you back.

    References

    • Bajaj, J. S., Silvey, S. G., Rogal, S., O’Leary, J. G., Patton, H., Morgan, T. R., Kanagalingam, G., Gentili, A., et al. (2024). Undiagnosed cirrhosis and hepatic encephalopathy in a national cohort of veterans with dementia. JAMA Network Open, 7(1), e2353965. https://doi.org/10.1001/jamanetworkopen.2023.53965
    • Silvey, S., Sterling, R. K., French, E., Godschalk, M., Gentili, A., Patel, N., & Bajaj, J. S. (2024). A possible reversible cause of cognitive impairment: undiagnosed cirrhosis and potential hepatic encephalopathy in patients with dementia. The American Journal of Medicine, 137(11), 1082-1087.e1. https://doi.org/10.1016/j.amjmed.2024.06.014
    • McPherson, S., Hardy, T., Dufour, J. F., Petta, S., Romero-Gomez, M., Allison, M., Oliveira, C. P., Francque, S., et al. (2017). Age as a confounding factor for the accurate non-invasive diagnosis of advanced NAFLD fibrosis. The American Journal of Gastroenterology, 112(5), 740-751. https://doi.org/10.1038/ajg.2016.453
    • Zeng, X., Yin, C., Sun, C. Y., Lu, C. H., Zhao, S. S., Gao, X. H., Chen, D. F., Wen, L. Z., et al. (2023). Prevalence and risk factors of covert hepatic encephalopathy in cirrhotic patients: a multicenter study in China. Journal of Digestive Diseases, 24(2), 122-132. https://doi.org/10.1111/1751-2980.13171
    • Sultanik, P., Kheloufi, L., Leproux, A., Bouzbib, C., Mouri, S., Santiago, A., Galanaud, D., Navarro, V., et al. (2024). Other causes of neurocognitive impairment than covert hepatic encephalopathy (CHE) are very frequent, either alone or associated with CHE, in cirrhotic patients with cognitive complaints. Alimentary Pharmacology & Therapeutics, 60(6), 749-764. https://doi.org/10.1111/apt.18148
    • Parikh, N. S., Wahbeh, F., Tapia, C., Ianelli, M., Liao, V., Jaywant, A., Kamel, H., Kumar, S., et al. (2024). Cognitive impairment and liver fibrosis in non-alcoholic fatty liver disease. BMJ Neurology Open, 6(1), e000543. https://doi.org/10.1136/bmjno-2023-000543
    • Li, Y. S., Xia, Y. G., Liu, Y. L., Jiang, W. R., Qiu, H. N., Wu, F., Li, J. B., & Lin, J. N. (2024). Metabolic-dysfunction associated steatotic liver disease-related diseases, cognition and dementia: a two-sample mendelian randomization study. PLoS One, 19(2), e0297883. https://doi.org/10.1371/journal.pone.0297883
    • Wang, J. Y., Bajaj, J. S., Wang, J. B., Shang, J., Zhou, X. M., Guo, X. L., Zhu, X., Meng, L. N., et al. (2019). Lactulose improves cognition, quality of life, and gut microbiota in minimal hepatic encephalopathy: a multicenter, randomized controlled trial. Journal of Digestive Diseases, 20(10), 547-556. https://doi.org/10.1111/1751-2980.12816
    • Vilstrup, H., Amodio, P., Bajaj, J., Cordoba, J., Ferenci, P., Mullen, K. D., Weissenborn, K., & Wong, P. (2014). Hepatic encephalopathy in chronic liver disease: 2014 practice guideline by the American Association for the Study of Liver Diseases and the European Association for the Study of the Liver. Hepatology, 60(2), 715-735. https://doi.org/10.1002/hep.27210
    • Bloom, P. P. (2025). The misdiagnosis and underdiagnosis of hepatic encephalopathy. Clinical and Translational Gastroenterology, 16(2), e00784. https://doi.org/10.14309/ctg.0000000000000784

    Related reading

  • Senior woman checks man's blood pressure at home.

    Weight-Adjusted Waist Index: Stroke Risk Screening in Hypertension

    Weight-Adjusted Waist Index: Stroke Risk Screening in Hypertension

    In hypertensive adults aged 60 and older, a higher weight-adjusted waist index predicted new stroke after body mass index and waist circumference were already accounted for; the top quartile, an index of 10.80 or above, carried 1.87 times the stroke hazard of the bottom quartile.

    Blood pressure visits record a cuff reading and a weight. The measurement that separates older hypertensive patients by stroke risk needs one more number, taken with a tape.

    The weight-adjusted waist index is waist circumference in centimeters divided by the square root of body weight in kilograms, and in older adults with hypertension it predicts incident stroke after body mass index and waist circumference are already in the model. The hypertension visit records a cuff reading and a weight; the measurement that separates these patients by stroke risk needs a tape, and confirming what it means takes body composition analysis.

    What the Xinjiang hypertension cohort found

    The index was proposed in a Korean nationwide cohort of 465,629 subjects, where it showed the best predictive performance for cardiovascular mortality among the anthropometric measures tested. Its stroke signal in hypertension comes from a hospital-based cohort at the People’s Hospital of Xinjiang Uygur Autonomous Region in China: 4,962 hypertensive individuals aged 60 years or older with no prior stroke. Over a median follow-up of 3.2 years there were 547 new-onset strokes.

    • Per standard deviation of the index, the adjusted hazard ratio for stroke was 1.30 (95% CI 1.18 to 1.42).
    • The top quartile, an index of 10.80 or above, carried a hazard ratio of 1.87 against the bottom quartile.
    • The model adjusted for body mass index, waist circumference, systolic and diastolic pressure, hypertension duration, diabetes, lipids, homocysteine, renal function, high-sensitivity C-reactive protein and antihypertensive, antidiabetic and lipid-lowering drugs.
    • Adding the index to established risk factors moved the C-statistic from 0.534 to 0.575, and its area under the curve for stroke, 0.632, exceeded that of body mass index and waist circumference.

    Mean body mass index was 22.37 in the lowest quartile and 25.93 in the highest. The patients carrying nearly double the stroke hazard were, by the scale, what most charts call mildly overweight at worst. This is a Chinese cohort, and the practice position is settled: a normal-BMI East Asian population is thin outside and fat inside, metabolically inflamed and insulin resistant. The bottom quartile is a reference group, not a healthy one, and the misclassified normal-weight patient is the subject of screening for the risk that BMI misclassifies.

    Why a waist index sees what body mass index misses

    Body mass index cannot tell muscle from fat, and waist circumference alone rises with overall size. Dividing waist by the square root of weight standardizes central adiposity for body size. The Xinjiang authors note the index is associated with a higher probability of having both high fat mass and low muscle mass, which is precisely the property that matters in geriatrics.

    The non-obvious consequence is arithmetic. Weight sits in the denominator. An older patient who loses muscle loses weight, body mass index improves, the belt size barely moves, and the index climbs. The chart records success while the index records sarcopenic wasting under an unchanged abdominal depot. For years the reflex in most clinics, mine included, was to praise that weight loss in an older hypertensive patient. In a patient over 60, weight falling with a stable waist is a reason to measure composition, not to congratulate.

    Two biological drivers carry the depot to the cerebral circulation. Visceral fat is an inflammatory organ: it sustains metaflammation, drives endothelial dysfunction and holds the patient in an insulin-resistant, proatherogenic state. Central adiposity also stokes sympathetic outflow and the renin-angiotensin system, which stiffens arteries, the change arterial stiffness testing quantifies, and makes pressure harder to control with every added drug. The third driver is structural. The hypertension visit is built around a cuff and a scale, waist circumference has no routine field in most workflows, and a food supply saturated with acellular carbohydrate and industrial seed oil builds the depot for years before weight crosses anyone’s threshold. In people rather than cohorts, the same depot shows up as aching in several places at once, covered in whether belly fat can cause chronic pain.

    How the signal holds up in newer cohorts

    Evidence from 2025 and 2026 carries the finding well beyond one Chinese hospital:

    • UK Biobank, 2026. In 398,270 participants without prior stroke, the index had the strongest associations among the obesity measures compared. The top quartile carried hazard ratios for ischemic stroke of 1.25 in men and 1.36 in women, and the index beat body mass index for ischemic stroke discrimination in both sexes (men, C-statistic 0.712 versus 0.688; women, 0.748 versus 0.726).
    • China Health and Retirement Longitudinal Study, 2025. Among 12,580 adults aged 45 and above, 727 had a stroke. The index predicted stroke in participants with hypertension (hazard ratio 1.13), and hypertension accounted for 12% of its total effect. Blood pressure control alone does not neutralize the depot.
    • ACCORD, 2025. In type 2 diabetes the index predicted congestive heart failure with a hazard ratio of 1.20 per standard deviation, beyond stroke alone.

    One disagreement belongs in the interpretation. The Xinjiang cohort reported an association with hemorrhagic stroke as well as ischemic stroke; in UK Biobank no significant association was observed for hemorrhagic stroke. The reproducible signal is ischemic. The Xinjiang data are single-region, rest on one baseline measurement and carry no physical activity or dietary data, which the authors state plainly. None of that weakens the case for measuring a waist. It limits how literally any one cut-off should be imported into a St. Louis panel. The same body composition lens has been turned on the brain, set out in how fat and muscle patterns relate to later dementia.

    Who to screen and what a high index changes

    • Adults aged 60 and older with hypertension, at every blood pressure visit, with waist measured by a consistent protocol.
    • Hypertensive patients with a normal or modestly elevated body mass index, particularly East Asian and South Asian patients.
    • Older patients whose weight is falling without a matching fall in waist circumference.
    • Patients with diabetes, dyslipidemia or fatty liver whose blood pressure is controlled but whose global risk has not been reassessed.

    Written selection criteria keep the list reproducible across clinicians.

    A high index should not, on its own, push antihypertensive intensification in a frail patient. It relocates the patient into active vascular prevention and aims treatment at the depot and at muscle: food composition, resistance and walking programs, sleep and alcohol, each prescribed with its physiological rationale, with the index and body composition repeated to show whether the waist moved relative to weight. Where pressure control is being tightened in an older patient, the standing reading matters as much as the seated one, as set out in what a seated blood pressure reading misses.

    What the measurements add

    Measura [Cardiometabolic and Autonomic Health Analysis] is a testing service; it measures and reports to the ordering physician and does not treat. Waist and weight belong in every visit. What Measura adds is the physiology behind the index:

    Standing orders and the wellness visit

    A waist circumference is worthless unless it is taken the same way every time, so it belongs in standing orders rather than in the memory of whoever rooms the patient. The annual wellness visit already structures risk review, cognition and falls; recording the index there, beside composition and vascular findings, turns a single anthropometric number into a trajectory (see annual wellness visit integration). The documented measures this testing supports are covered in quality measures that cardiometabolic testing supports. Unmeasured is unmanaged, and a stroke risk hiding behind a normal body mass index is the most unmanaged risk in the room.

    Frequently asked questions

    How is the weight-adjusted waist index calculated and interpreted?

    Divide waist circumference in centimeters by the square root of weight in kilograms. In the Xinjiang cohort the mean was 9.99 and the highest-risk quartile began at 10.80; a Chinese longitudinal cohort of 13,046 adults found cardiovascular risk rising above an inflection near 10. Treat these as cohort-specific reference points rather than universal thresholds, and track change within the patient. The same depot logic underlies metaflammation screening in primary care.

    Does the index replace body mass index in cardiovascular risk assessment?

    It works best alongside it. The derivation study found the index combined with body mass index was the strongest pairing in both diagnostic and prognostic models, and the stroke cohorts adjusted for body mass index and still found an independent signal. Body mass index describes size; the index describes central fat relative to size. Other overlooked cardiovascular signals in primary care are reviewed in erectile dysfunction as a cardiovascular risk marker.

    Should a high index change blood pressure targets in an older patient?

    The index predicts stroke; it does not set a pressure target, and the Xinjiang association held after adjustment for pressure and medication. In older adults the sound sequence is to document orthostatic responses and autonomic function before intensifying, then treat the depot and muscle directly. Medication decisions remain with the treating physician. Baseline measurement before any regimen change is argued in deprescribing starts with a baseline, not a drug list.

    Why pair the index with fall and bone assessment in geriatrics?

    A rising index can mean muscle is disappearing beneath a stable waist, and lost muscle is a fall risk in its own right. The same hypertensive patient is often on several pressure-lowering drugs and low in vitamin D. Composition, balance and vitamin D status belong in the same encounter as the tape measure, as discussed in vitamin D screening and what falls risk adds.

    Does a normal ankle-brachial index rule out vascular disease in these patients?

    A normal resting value does not exclude disease, particularly in older patients with diabetes or kidney disease, where calcified, incompressible arteries falsely raise the reading. That is why toe-brachial measurement and arterial stiffness sit alongside it in a patient with a high waist index. The mechanism and the patterns to watch for are explained in why a normal ankle-brachial index can be misleading.

    Bring body composition into hypertension care

    See how the Measura protocol adds composition, vascular and autonomic measurements to the blood pressure visit, and how findings return to your chart.

    4477 Woodson Rd, Suite 201, St. Louis, MO 63134. Monday to Friday, 9:00 a.m. to 5:00 p.m. Please do not send symptoms, diagnoses or images through a web form — a website form is not a secure medical channel. Send your name and number and we will call you back.

    References

    • Hu, J., Cai, X., Song, S., Zhu, Q., Shen, D., Yang, W., Hong, J., Luo, Q., et al. (2024). Association between weight-adjusted waist index with incident stroke in the elderly with hypertension: a cohort study. Scientific Reports, 14(1), 25614. https://doi.org/10.1038/s41598-024-76709-y
    • Park, Y., Kim, N. H., Kwon, T. Y., & Kim, S. G. (2018). A novel adiposity index as an integrated predictor of cardiometabolic disease morbidity and mortality. Scientific Reports, 8(1), 16753. https://doi.org/10.1038/s41598-018-35073-4
    • Li, F., Wang, Z. Y., Qi, S. S., Xu, Y. M., & Shi, C. H. (2026). Predictive value of traditional and novel obesity indices for stroke and its subtypes across sexes and glucose status: toward precision prevention strategies. Journal of the American Heart Association, 15(6), e043083. https://doi.org/10.1161/JAHA.125.043083
    • Xu, F., Liu, H., Li, M., Zhang, M., Chen, X., & Hou, M. (2025). Hypertension mediates the association between weight-adjusted waist index and new onset stroke risk in middle-aged and older Chinese adults: evidence from the CHARLS study. Frontiers in Neurology, 16, 1587176. https://doi.org/10.3389/fneur.2025.1587176
    • Liu, M., Pei, J., Zeng, C., Xin, Y., Tang, P., & Hu, X. (2025). Associations and predictive value of weight-adjusted waist index for cardiovascular outcomes in type 2 diabetes: evidence from the ACCORD study. Nutrition Journal, 24(1), 184. https://doi.org/10.1186/s12937-025-01251-0
    • Wang, J., Zhu, A., Zeng, R., Chen, L., Xie, F., Zhu, K., Fan, T., Ye, D., et al. (2025). A J-shaped association between weight-adjusted waist index and cardiovascular disease: a longitudinal study from the CHARLS database. BMC Public Health, 25(1), 4041. https://doi.org/10.1186/s12889-025-25127-4

    Related reading

  • Dr. Gurpreet Singh Padda presenting beside the title card The Nicotine Paradox: It Was Never the Molecule, It's Where You Put It, The Angry Gut, Chapter 32

    The Cholinergic Anti-Inflammatory Pathway: What You Can Measure

    The Nicotine Paradox: It Was Never the Molecule, It's Where You Put It | The Angry Gut, Chapter 32

    The Cholinergic Anti-Inflammatory Pathway: What You Can Measure

    The cholinergic anti-inflammatory pathway is acetylcholine switching off TNF release from macrophages through the alpha-7 receptor, a finding mapped in mice rather than people. What a practice can document is autonomic, vascular, cardiometabolic, body-composition and cognitive function in the same patient; motility and disease activity belong to gastroenterology.

    Patients bring this pathway to clinic as a question about nicotine. The receptor biology is real, the delivery question is unanswered, and the measurable part of it sits outside the colon.

    The cholinergic anti-inflammatory pathway usually reaches a clinic as a question, not a prescription. A patient whose distal ulcerative colitis surfaced eleven months after she stopped smoking asks whether she should start again, and nobody has answered her, because the honest sentence sounds like an endorsement of tobacco. The answer is no. The useful work is separating three claims that get merged: an immune receptor, a motor receptor and a delivery route. The video above closes The Angry Gut by Dr. Gurpreet Singh Padda, MD, MBA, MHP, and Ami Michelle Grimes.

    The cholinergic anti-inflammatory pathway: two receptors, two arguments

    The immune arm is better mapped and it is not human. Acetylcholine cannot switch off macrophage TNF release without the alpha-7 subunit, and in mice bred without it the vagal suppression of TNF disappears entirely. In an inflamed gut wall it sits on monocytes and macrophages rather than neurons. Rodent work throughout.

    Fast transmission between enteric neurons runs on a different assembly: blocking the alpha-3-beta-4 type drops evoked responses, while an alpha-7 antagonist had no effect at any developmental age. Motor and immune actions are separable, and evidence that looks contradictory stops conflicting once sorted that way.

    The human anchor is thinner and more interesting than either. Surgical colon answered a nicotinic stimulus with action potentials in 51 neurons, drawn from 20 myenteric ganglia in 19 patients and bursting 2 to 23 times near 5.3 Hz, while only about 8% of the myenteric neurons responded at all, which the authors call low. The same tissue bank puts myenteric density near 84 neurons per square millimeter in sigmoid and rectum against 38 in the ascending colon: twice the wiring, where distal disease sits.

    What the trials support, and where the ceiling is

    Pooled data put transdermal nicotine ahead of placebo for inducing remission. Then the ceiling, from the same review: against prednisone or mesalamine, no advantage. A broader meta-analysis found no efficacy, with a relative risk of 1.40 whose interval crosses one, and harm at 1.95. Harm replicated where benefit did not.

    The randomized rectal route used a 6 mg liquid preparation and failed, with remission at 27% against 33% on placebo and the authors calling the enemas well tolerated but not efficacious. Tolerability was the one problem local delivery solved: one of 104 patients stopped for harm.

    The position, stated exactly. The formulation is the claim: a small dose held against the distal colonic mucosa, not a whole patient dosed through the skin. No published trial of a nicotine suppository exists, in any indication, anywhere; the group that built such formulations assayed release in a dish and stopped there. A failed patch and a failed liquid enema are not evidence against a preparation nobody has administered, and an untested preparation is not a proven one. None of this is a reason for a patient to use nicotine in any form.

    On motility, keep two claims apart. The evacuation claim is supported in humans: transient high-amplitude propagated contractions and faster colonic transit followed a high dose in healthy subjects, mass peristalsis recorded rather than inferred from a receptor map. The migrating motor complex claim is not, and no controlled human trial of nicotine for a stalled motor complex exists. Motility studies are not in this test library; they belong to gastroenterology, with endoscopy and stool markers.

    Three measurement failures worth carrying into your own practice

    First, the tissue was never sampled. No study has measured nicotine concentration in rectal mucosal tissue, so the local-delivery premise is inferred from serum. A mechanism assayed one compartment away from where it supposedly acts is a hypothesis, not a demonstration.

    Second, the level did not predict the patient. In the liquid enema pilot, 4 of 10 patients had adverse events while serum nicotine was low or undetectable. Managing by concentration would have missed all of them.

    Third, a dosing signal sat unused in an adverse-event table. In the carbomer enema study the subjects who reported side effects were all female lifelong nonsmokers of low body weight, and inflamed bowel absorbed the dose more slowly, peaking at 60 minutes against 45. Exposure scales to the compartment holding it, which body weight alone does not describe.

    Who to test, what changes, and how the baseline is captured

    Measura [Cardiometabolic and Autonomic Health Analysis] measures cardiometabolic and autonomic function. It does not treat, and it does not grade disease activity in a bowel. What it documents is the physiology a cholinergic drug discussion assumes and nobody records.

    What a finding changes is modest and concrete. An autonomic or vascular abnormality documented before a cessation program, or before any drug with cholinergic or sympathomimetic effects, becomes the comparator for everything after it. Without one, a later symptom has nothing to be measured against.

    Workflow decides whether any of this happens. Standing orders capture a baseline without a fresh decision at every visit, the annual wellness visit is the natural slot, and getting results into the record turns a study into documentation that supports MIPS and HEDIS quality reporting. In older patients the same visit documents cognitive assessment and fall prevention, and selection criteria keep testing pointed where a result changes something. The patient-facing version is what your patients are reading.

    The strongest case against all of it

    The strongest argument is not danger. It is that the molecule has had its chance: four preparations, two groups, three decades, harm replicating and benefit not. The 6 mg liquid vehicle is done, and so is the patch as monotherapy.

    What does not follow is that one dose in one vehicle settles a route, particularly when that trial never recorded how long its own enemas stayed in, and when 3 of 10 patients in an earlier pilot quit inside a week, unable to retain the liquid. One caution runs against my own reading: some blood leaving the lower rectum skips the liver altogether, so a preparation sitting low could put more drug per milligram into the rest of the patient, not less. Unmeasured either way.

    The honest mechanistic route runs away from the molecule. Rats with postoperative ileus were given a serotonin receptor agonist, which pushed cholinergic neurons to release more acetylcholine and quieted the macrophages of the muscle layer; ganglionic blockade, or an alpha-7 antagonist, abolished it, and motility and white-cell infiltration improved together. Rodent data, and the effective drug was serotonergic. No nicotinic agonist has ever been developed as a gut prokinetic.

    So the instruction is unchanged. Counsel against resuming smoking, document the interval from quit date to diagnosis, offer no nicotine, and do not let the awkwardness of the question substitute for an answer: a patient who carries it alone for two years has been managed by silence. Rescue is not repair. Every study named here sits with its limits in the companion deep dive, and specialty applications covers where this fits by discipline.

    Frequently asked questions

    Should nicotine ever be offered to a patient with ulcerative colitis?

    No. The patch showed no advantage against prednisone or mesalamine, the randomized rectal trial failed, and the broader pooled analysis found no efficacy alongside more harm. Disease-directed therapy stays with gastroenterology. Counsel against resuming smoking and document the cessation-to-onset interval. See the clinical rationale for testing.

    Does the negative enema trial close the question about the route?

    It closes that dose in that vehicle. Retention was never recorded, tissue concentration has never been measured in any study, and no suppository has reached a human being in any indication. An absence of evidence licenses a study rather than a prescription, and it is not the same finding as a negative result. See what a result can and cannot tell you.

    Can this testing measure gut motility or disease activity?

    No. Motility studies, endoscopy, imaging and stool markers sit with gastroenterology; they are the correct tests for the bowel itself. What arrives in your record instead is cardiometabolic, autonomic, vascular, body-composition and cognitive measurement in the same patient, a different question honestly labeled. See how the report is interpreted.

    Is heart rate variability a measure of the cholinergic anti-inflammatory reflex?

    No, and presenting it that way overstates it badly. Variability quantifies beat-to-beat variation in cardiac intervals. The alpha-7 mechanism was established in mice, on macrophages rather than neurons, and no human study ties a variability figure to cytokine suppression. Use it as a repeatable measure of tone. See what the variability number means.

    What belongs in the chart when a patient raises this?

    The quit date and the interval to diagnosis, the extent and location of disease, what has already been tried in the standard sequence, and any reflux history, since transdermal nicotine lowers pressure at the base of the esophagus and raises acid exposure. Add an autonomic and vascular baseline before cessation. Standing orders make screening reproducible.

    Build the baseline before the conversation

    See how the protocol captures an autonomic, vascular and metabolic baseline inside a visit you already have scheduled, and how those results arrive in your record.

    4477 Woodson Rd, Suite 201, St. Louis, MO 63134. Monday to Friday, 9:00 a.m. to 5:00 p.m. Please do not send symptoms, diagnoses or images through a web form — a website form is not a secure medical channel. Send your name and number and we will call you back.

    References

    • Wang, H., Yu, M., Ochani, M., Amella, C. A., Tanovic, M., Susarla, S., Li, J. H., Wang, H., Yang, H., Ulloa, L., Al-Abed, Y., Czura, C. J., & Tracey, K. J. (2003). Nicotinic acetylcholine receptor alpha7 subunit is an essential regulator of inflammation. Nature, 421(6921), 384-388. https://doi.org/10.1038/nature01339
    • Elfers, K., Sehnert, A. S., Wagner, A., Zwirner, U., Linge, H., Kulik, U., Poehnert, D., Winny, M., Gundert, B., Aselmann, H., & Mazzuoli-Weber, G. (2024). Functional and structural investigation of myenteric neurons in the human colon. Gastro Hep Advances, 4(1), 100537. https://doi.org/10.1016/j.gastha.2024.08.016
    • Foong, J. P. P., Hirst, C. S., Hao, M. M., McKeown, S. J., Boesmans, W., Young, H. M., Bornstein, J. C., & Vanden Berghe, P. (2015). Changes in nicotinic neurotransmission during enteric nervous system development. The Journal of Neuroscience, 35(18), 7106-7115. https://doi.org/10.1523/JNEUROSCI.4175-14.2015
    • Tsuchida, Y., Hatao, F., Fujisawa, M., Murata, T., Kaminishi, M., Seto, Y., Hori, M., & Ozaki, H. (2011). Neuronal stimulation with 5-hydroxytryptamine 4 receptor induces anti-inflammatory actions via alpha7nACh receptors on muscularis macrophages associated with postoperative ileus. Gut, 60(5), 638-647. https://doi.org/10.1136/gut.2010.227546
    • McGrath, J., McDonald, J. W. D., & Macdonald, J. K. (2004). Transdermal nicotine for induction of remission in ulcerative colitis. Cochrane Database of Systematic Reviews(4), CD004722. https://doi.org/10.1002/14651858.CD004722.pub2
    • Nikfar, S., Ehteshami-Ashar, S., Rahimi, R., & Abdollahi, M. (2010). Systematic review and meta-analysis of the efficacy and tolerability of nicotine preparations in active ulcerative colitis. Clinical Therapeutics, 32(14), 2304-2315. https://doi.org/10.1016/j.clinthera.2011.01.004
    • Ingram, J. R., Thomas, G. A. O., Rhodes, J., Green, J. T., Hawkes, N. D., Swift, J. L., Srivastava, E. D., Evans, B. K., Williams, G. T., Newcombe, R. G., Courtney, E., & Pillai, S. (2005). A randomized trial of nicotine enemas for active ulcerative colitis. Clinical Gastroenterology and Hepatology, 3(11), 1107-1114. https://doi.org/10.1016/s1542-3565(05)00849-9
    • Coulie, B., Camilleri, M., Bharucha, A. E., Sandborn, W. J., & Burton, D. (2001). Colonic motility in chronic ulcerative proctosigmoiditis and the effects of nicotine on colonic motility in patients and healthy subjects. Alimentary Pharmacology & Therapeutics, 15(5), 653-663. https://doi.org/10.1046/j.1365-2036.2001.00959.x
    • Sandborn, W. J., Tremaine, W. J., Leighton, J. A., Lawson, G. M., Zins, B. J., Compton, R. F., Mays, D. C., Lipsky, J. J., Batts, K. P., Offord, K. P., Hurt, R. D., & Green, J. (1997). Nicotine tartrate liquid enemas for mildly to moderately active left-sided ulcerative colitis unresponsive to first-line therapy: A pilot study. Alimentary Pharmacology & Therapeutics, 11(4), 663-71. https://doi.org/10.1046/j.1365-2036.1997.00208.x
    • Green, J. T., Thomas, G. A., Rhodes, J., Evans, B. K., Russell, M. A., Feyerabend, C., Fuller, G. S., Newcombe, R. G., & Sandborn, W. J. (1997). Pharmacokinetics of nicotine carbomer enemas: A new treatment modality for ulcerative colitis. Clinical Pharmacology and Therapeutics, 61(3), 340-8. https://doi.org/10.1016/S0009-9236(97)90167-3

    Related reading